Drug Database · Clinicians

Trastuzumab deruxtecan

Brands (1) EnhertuShow all

Human epidermal growth factor receptor 2 (HER2) inhibitor PH FDA category

Rx · Prescription drug1 PH productVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 7e67e73e-ddf4-4e4d-8b50-09d7514910b6, version date May 15, 2026 (Enhertu · Daiichi Sankyo Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab…
  • as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.
  • HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an…
  • as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in…
  • HER2-Low and HER2-Ultralow Metastatic Breast Cancer as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow…
  • as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the…
  • HER2-Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer as monotherapy for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2…
  • HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab, and pertuzumab (THP). (1.1) as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.

(1.1) HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test. (1.2) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

(1.2) HER2-Low and HER2-Ultralow Metastatic Breast Cancer as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting. (1.3) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

(1.3) HER2-Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer as monotherapy for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-authorized test, and who have received a prior systemic therapy* (1.4) HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. (1.5) HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* (1.6) * These indications are approved under accelerated approval based on objective response rate and duration of response.

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. (14.3, 14.5) 1.1 HER2-Positive Early Breast Cancer ENHERTU followed by a taxane, trastuzumab, and pertuzumab (THP) is indicated for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer as determined by an FDA-authorized test [see Dosage and Administration (2.1)].

ENHERTU is indicated for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment. 1.2 HER2-Positive Metastatic Breast Cancer ENHERTU, in combination with pertuzumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test [see Dosage and Administration (2.1)]. ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. 1.3 HER2-Low and HER2-Ultralow Metastatic Breast Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting [see Dosage and Administration (2.1)].

HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy [see Dosage and Administration (2.1)]. 1.4 HER2-Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-authorized test, and who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.4)].

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.5 HER2-Positive Locally Advanced or Metastatic Gastric Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. 1.6 HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.6)].

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Contraindications

4 CONTRAINDICATIONS None. None. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine. (2.2, 2.4)
  • For intravenous infusion only. Do not administer as an intravenous push or bolus. DO NOT use Sodium Chloride Injection, USP. (2.4)
  • Premedicate for prevention of chemotherapy-induced nausea and vomiting. (2.2)
  • HER2-Positive Early Breast Cancer Neoadjuvant: ENHERTU 5.4 mg/kg every 3 weeks for 4 cycles, followed by THP regimen for 4 cycles. (2.2, 2.3)
  • Post Neoadjuvant: ENHERTU 5.4 mg/kg every 3 weeks for 14 cycles unless disease recurrence or unacceptable toxicity. (2.2, 2.3)
  • HER2-Positive, HER2-Low, or HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and HER2-Positive (IHC 3+) Solid Tumors: ENHERTU 5.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity. (2.2, 2.3)
  • HER2-Positive First-line Metastatic Breast Cancer: ENHERTU 5.4 mg/kg every 3 weeks in combination with pertuzumab until disease progression or unacceptable toxicity. Cycle 1, Day 1: ENHERTU 5.4 mg/kg followed by pertuzumab 840 mg. (2.2, 2.3)
  • Subsequent cycles, Day 1: ENHERTU 5.4 mg/kg followed by pertuzumab 420 mg. (2.2, 2.3)
  • HER2-Positive Gastric Cancer: 6.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity. (2.2, 2.3)
  • Management of adverse reactions (ILD, neutropenia, thrombocytopenia, or left ventricular dysfunction) may require temporary interruption, dose …
2.1 Patient Selection HER2-Positive Early Breast Cancer

2.1 Patient Selection HER2-Positive Early Breast Cancer Select patients for the treatment of HER2-positive early breast cancer with ENHERTU based on HER2-positive (IHC 3+ or ISH+) status [see Clinical Studies (14.1)]. HER2-Positive Metastatic Breast Cancer Select patients for treatment of unresectable or metastatic HER2-positive breast cancer with ENHERTU in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+) [see Clinical Studies (14.2)].

HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Select patients for treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer with ENHERTU based on HER2 expression [see Clinical Studies (14.3)]. HER2-Mutant Unresectable or Metastatic NSCLC Select patients for the treatment of unresectable or metastatic HER2-mutant NSCLC with ENHERTU based on the presence of activating HER2 (ERBB2) mutations in tumor or plasma specimens [see Clinical Studies (14.4)].

If no mutation is detected in a plasma specimen, test tumor tissue. HER2-Positive Locally Advanced or Metastatic Gastric Cancer Select patients with locally advanced or metastatic HER2-positive gastric cancer based on HER2 protein overexpression or HER2 gene amplification (IHC 3+ or IHC 2+/ISH+). Reassess HER2 status if it is feasible to obtain a new tumor specimen after prior trastuzumab-based therapy and before treatment with ENHERTU.

HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors Select patients for treatment of unresectable or metastatic solid tumors with ENHERTU based on HER2-positive (IHC 3+) specimens [see Clinical Studies (14.6)]. An FDA-authorized test for the detection of HER2-positive (IHC 3+) solid tumors for treatment with ENHERTU is not currently available.

Additional Patient Selection Information Information on FDA-authorized tests for the detection of HER2 protein expression, HER2 gene amplification, and activating HER2 mutations is available at: http://www.fda.gov/CompanionDiagnostics.

2.2 Recommended Dosage

2.2 Recommended Dosage Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine. Slow or interrupt the infusion rate if the patient develops infusion-related symptoms. Permanently discontinue ENHERTU in case of severe infusion reactions. Premedication ENHERTU is highly emetogenic [see Adverse Reactions (6.1)], which includes delayed nausea and/or vomiting.

Administer prophylactic antiemetic medications per local institutional guidelines for prevention of chemotherapy-induced nausea and vomiting. The recommended dosages for ENHERTU as monotherapy and ENHERTU in combination with pertuzumab are presented in Table 1. Administer ENHERTU as an intravenous infusion [see Dosage and Administration (2.4)].

Table 1: Recommended Dosage Indication Recommended ENHERTU Dosage Duration of Therapy As Monotherapy HER2-Positive Early Breast Cancer – Post Neoadjuvant Treatment ENHERTU 5.4 mg/kg every 3 weeks 14 cycles unless disease recurrence or unacceptable toxicity HER2-Positive, HER2-Low, or HER2-Ultralow Metastatic Breast Cancer, HER2-Mutant Unresectable or Metastatic NSCLC, and HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy ENHERTU 5.4 mg/kg every 3 weeks Until disease progression or unacceptable toxicity HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy ENHERTU 6.4 mg/kg every 3 weeks Until disease progression or unacceptable toxicity In Combination HER2-Positive Metastatic Breast Cancer in combination with pertuzumab Cycle 1, Day 1: ENHERTU 5.4 mg/kg, followed by pertuzumab 840 mg Administer pertuzumab 30 minutes after ENHERTU. Subsequent cycles, Day 1: ENHERTU 5.4 mg/kg, followed by pertuzumab 420 mg every 3 weeks Until disease progression or unacceptable toxicity In Sequence HER2-Positive Early Breast Cancer followed by THP ENHERTU 5.4 mg/kg every 3 weeks for 4 cycles, followed by THP regimen THP regimen: a taxane concurrent with trastuzumab (6 mg/kg every 3 weeks) and pertuzumab (an initial dose of 840 mg followed by 420 mg every 3 weeks) for 4 cycles 4 cycles of ENHERTU followed by 4 cycles of THP.

2.3 Dosage Modifications for Adverse Reactions

2.3 Dosage Modifications for Adverse Reactions Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of ENHERTU as described in Tables 2 and 3. Refer to the Prescribing Information for pertuzumab for dose modification recommendations. Pertuzumab is not to be administered as a single agent.

Do not re-escalate the ENHERTU dose after a dose reduction is made. If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle. Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.

Table 2: Dosage Reduction Schedule Dose Reduction Schedule Breast Cancer, NSCLC, and IHC 3+ Solid Tumors Gastric Cancer Recommended starting dose 5.4 mg/kg 6.4 mg/kg First dose reduction 4.4 mg/kg 5.4 mg/kg Second dose reduction 3.2 mg/kg 4.4 mg/kg Requirement for further dose reduction Discontinue treatment. Discontinue treatment.

Table 3: Dosage Modifications for Adverse Reactions Adverse Reaction Severity Treatment Modification Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v.5.0). Interstitial Lung Disease (ILD)/ Pneumonitis In the adjuvant setting, if drug-induced ILD is suspected, rule out radiotherapy-related pneumonitis.

If only radiotherapy-related pneumonitis is suspected, consider interruption of ENHERTU for Grade 2 and permanently discontinue ENHERTU for Grade ≥3. [see Warnings and Precautions (5.1)] Asymptomatic ILD/pneumonitis (Grade 1) Interrupt ENHERTU until resolved to Grade 0, then: if resolved in 28 days or less from date of onset, maintain dose. if resolved in greater than 28 days from date of onset, reduce dose one level (see Table 2). consider corticosteroid treatment as soon as ILD/pneumonitis is suspected. Symptomatic ILD/pneumonitis (Grade 2 or greater) Permanently discontinue ENHERTU.

Promptly initiate corticosteroid treatment as soon as ILD/pneumonitis is suspected. Neutropenia [see Warnings and Precautions (5.2)] Grade 3 (less than 1.0 to 0.5 × 10 9 /L) Interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. Grade 4 (less than 0.5 × 10 9 /L) Interrupt ENHERTU until resolved to Grade 2 or less.

Reduce dose by one level (see Table 2). Febrile Neutropenia [see Warnings and Precautions (5.2)] Absolute neutrophil count of less than 1.0 × 10 9 /L and temperature greater than 38.3°C or a sustained temperature of 38°C or greater for more than one hour Interrupt ENHERTU until resolved. Reduce dose by one level (see Table 2).

Thrombocytopenia [see Adverse Reactions (6.1)] Grade 3 (platelets less than 50 to 25 × 10 9 /L) Interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose. Grade 4 (platelets less than 25 × 10 9 /L) Interrupt ENHERTU until resolved to Grade 1 or less. Reduce dose by one level (see Table 2). Left Ventricular Dysfunction (LVD) [see Warnings and Precautions (5.3)] Left Ventricular Ejection Fraction (LVEF) greater than 45% and absolute decrease from baseline is 10% to 20% Continue treatment with ENHERTU.

LVEF 40% to 45% And absolute decrease from baseline is less than 10% Continue treatment with ENHERTU. Repeat LVEF assessment within 3 weeks. And absolute decrease from baseline is 10% to 20% Interrupt ENHERTU. Repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU.

If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. LVEF less than 40% or absolute decrease from baseline is greater than 20% Interrupt ENHERTU. Repeat LVEF assessment within 3 weeks. If LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed, permanently discontinue ENHERTU.

Symptomatic congestive heart failure (CHF) Permanently discontinue ENHERTU.

2.4 Preparation and Administration

2.4 Preparation and Administration In order to prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is ENHERTU (fam-trastuzumab deruxtecan-nxki) and not trastuzumab or ado-trastuzumab emtansine. Reconstitute and further dilute ENHERTU prior to intravenous infusion. Use appropriate aseptic technique.

ENHERTU (fam-trastuzumab deruxtecan-nxki) is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Reconstitution Reconstitute immediately before dilution. More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted ENHERTU solution required, and the number of vial(s) of ENHERTU needed [see Dosage and Administration (2.2)].

Reconstitute each 100 mg vial by using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection, USP into each vial to obtain a final concentration of 20 mg/mL. Swirl the vial gently until completely dissolved. Do not shake. If not used immediately, store the reconstituted ENHERTU vials in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours from the time of reconstitution, protect the vial from light.

Do not freeze. The product does not contain a preservative. Discard unused reconstituted ENHERTU after 24 hours refrigerated. Dilution Withdraw the calculated amount from the vial(s) using a sterile syringe. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

The solution should be clear and colorless to light yellow. Do not use if visible particles are observed or if the solution is cloudy or discolored. Dilute the calculated volume of reconstituted ENHERTU in an intravenous infusion bag containing 100 mL of 5% Dextrose Injection, USP. DO NOT use Sodium Chloride Injection, USP.

ENHERTU is compatible with an infusion bag made of polyvinylchloride or polyolefin (copolymer of ethylene and polypropylene). Gently invert the infusion bag to thoroughly mix the solution. Do not shake. Cover the infusion bag to protect from light. Discard any unused portion left in the vials. Administration If not used immediately, store the diluted ENHERTU in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours or at room temperature between 20°C to 25°C (68°F to 77 °F) for up to 4 hours including preparation and infusion time.

Protect from light. Do not freeze. The maximum time from reconstitution of the vial through the end of administration should not exceed 24 hours. If the prepared infusion solution was stored refrigerated (2°C to 8°C [36°F to 46°F]), allow the solution to reach room temperature prior to administration. Cover the infusion bag to protect from light.

Administer ENHERTU as an intravenous infusion only with an infusion set made of polyolefin or polybutadiene. Administer ENHERTU with a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter. Do NOT administer as an intravenous push or bolus. Cover the infusion bag to protect from light during administration.

Do not mix ENHERTU with other drugs or administer other drugs through the same intravenous line. First infusion: Administer infusion over 90 minutes. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment No dose adjustment of ENHERTU is recommended in patients with mild (creatinine clearance [CLcr] 60 to <90 mL/min) or moderate (CLcr 30 to <60 mL/min) renal impairment [see Clinical Pharmacology (12.3)]. A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment [see Warnings and Precautions (5.1)]. Monitor patients with moderate renal impairment more frequently. The recommended dosage of ENHERTU has not been established for patients with severe renal impairment (CLcr <30 mL/min) [see Clinical Pharmacology (12.3)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment No dose adjustment of ENHERTU is recommended in patients with mild (total bilirubin ≤ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST) or moderate (total bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment. In patients with moderate hepatic impairment, due to potentially increased exposure, monitor for increased adverse reactions related to the topoisomerase inhibitor, DXd [see Dosage and Administration (2.3)].

The recommended dosage of ENHERTU has not been established for patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST) [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of ENHERTU have not been established in pediatric patients. Animal Data Juvenile animal studies have not been conducted with fam-trastuzumab deruxtecan-nxki. In a six-week repeat-dose toxicity study in rats, intravenous administration of fam-trastuzumab deruxtecan-nxki resulted in incisor tooth toxicity including single cell necrosis in the base area (e.g., ameloblasts, odontoblasts) and degeneration of the enamel at ≥60 mg/kg (approximately ≥9 times the human recommended dose of 5.4 mg/kg based on AUC), abnormal formation or hypoplasia of the dentin, hemorrhage in the sub-enamel organ tissue, and focal lack of the cementum at 197 mg/kg (approximately 19 times the human recommended dose of 5.4 mg/kg based on AUC).

Degeneration of the enamel organ, abnormal dentin formation, hemorrhage in the sub-enamel organ tissue, focal lack of the cementum, and root fracture were observed at 197 mg/kg following a 9-week recovery period.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use ENHERTU as Monotherapy Of the 2233 patients treated with ENHERTU 5.4 mg/kg, 28% were 65 years or older and 6% were 75 years or older. No overall differences in efficacy within clinical studies were observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged 65 years or older (56%) as compared to younger patients (49%).

Of the 125 patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg in DESTINY-Gastric01, 56% were 65 years or older and 14% were 75 years or older. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients.

ENHERTU in Combination with Pertuzumab In patients with HER2-positive unresectable or metastatic breast cancer treated with ENHERTU 5.4 mg/kg in combination with pertuzumab (N=431), 17% were 65 years or older and 3% were 75 years or older. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients.

ENHERTU followed by THP Of the 320 patients with HER2-positive early breast cancer treated with ENHERTU 5.4 mg/kg followed by THP, 12% were 65 years or older and 1.6% were 75 years or older. No overall difference in efficacy was observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged 65 years or older (38%) as compared to younger patients (30%).

Administration

2.4 Preparation and Administration In order to prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is ENHERTU (fam-trastuzumab deruxtecan-nxki) and not trastuzumab or ado-trastuzumab emtansine. Reconstitute and further dilute ENHERTU prior to intravenous infusion. Use appropriate aseptic technique. ENHERTU (fam-trastuzumab deruxtecan-nxki) is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Reconstitution Reconstitute immediately before dilution. More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted ENHERTU solution required, and the number of vial(s) of ENHERTU needed [see Dosage and Administration (2.2) ] . Reconstitute each 100 mg vial by using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection, USP into each vial to obtain a final concentration of 20 mg/mL. Swirl the vial gently until completely dissolved. Do not shake . If not used immediately, store the reconstituted ENHERTU vials in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours from the time of reconstitution, protect the vial from light. Do not freeze . The product does not contain a preservative. Discard unused reconstituted ENHERTU after 24 hours refrigerated. Dilution Withdraw the calculated amount from the vial(s) using a sterile syringe. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. The solution should be clear and colorless to light yellow. Do not use if visible particles are observed or if the solution is cloudy or discolored. Dilute the calculated volume of reconstituted ENHERTU in an intravenous infusion bag containing 100 mL of 5% Dextrose Injection, USP . DO NOT use Sodium Chloride Injection, USP. ENHERTU is compatible with an infusion bag made of polyvinylchloride or polyolefin (copolymer of ethylene and polypropylene). Gently invert the infusion bag to thoroughly mix the solution. Do not shake . Cover the infusion bag to protect from light. Discard any unused portion left in the vials. Administration If not used immediately, store the diluted ENHERTU in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours or at room temperature between 20°C to 25°C (68°F to 77 °F) for up to 4 hours including preparation and infusion time. Protect from light. Do not freeze . The maximum time from reconstitution of the vial through the end of administration should not exceed 24 hours. If the prepared infusion solution was stored refrigerated (2°C to 8°C [36°F to 46°F]), allow the solution to reach room temperature prior to administration. Cover the infusion bag to protect from light. Administer ENHERTU as an intravenous infusion only with an infusion set made of polyolefin or polybutadiene. Administer ENHERTU with a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter. Do NOT administer as an intravenous push or bolus. Cover the infusion bag to protect from light during administration. Do not mix ENHERTU with other drugs or administer other drugs through the same intravenous line. First infusion: Administer infusion over 90 minutes. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated.

US FDA label

Dosage forms

Philippines

  • Powder for concentrate for solution for infusion: 100 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Trastuzumab deruxtecan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Trastuzumab deruxtecan
Package insert
EnhertuTrastuzumab deruxtecan
100 mg Powder for Concentrate for Solution for Infusion (IV)Type I amber glass vial and sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/ aluminum yellow flip-off crimp cap (Box of 1 vial)
RxVAT-exempt
Baxter Oncology GmbHGermany
Importer: AstraZeneca Pharmaceuticals (Phils.), Inc.
BR-1464
Jan 15, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS For injection: 100 mg of fam-trastuzumab deruxtecan-nxki as a white to yellowish white lyophilized powder in a single-dose vial for reconstitution and further dilution For injection: 100 mg lyophilized powder in a single-dose vial (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Neutropenia: Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. Manage through treatment interruption or dose reduction. (2.3, 5.2)
  • Left Ventricular Dysfunction (LVD): Assess left ventricular ejection fraction (LVEF) prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage through treatment interruption or discontinuation. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure (CHF). (2.3, 5.3)
5.1 Interstitial Lung Disease/Pneumonitis

5.1 Interstitial Lung Disease/Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU [see Adverse Reactions (6.1)]. A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms.

Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic (Grade 1) ILD, consider corticosteroid treatment (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). Withhold ENHERTU until recovery [see Dosage and Administration (2.3)].

In cases of symptomatic ILD (Grade 2 or greater), promptly initiate systemic corticosteroid treatment (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks. Permanently discontinue ENHERTU in patients who are diagnosed with symptomatic (Grade 2 or greater) ILD [see Dosage and Administration (2.3)].

HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ENHERTU as Monotherapy In patients treated with ENHERTU 5.4 mg/kg, ILD occurred in 12% of patients. Median time to first onset was 5.5 months (range: 0.9 to 31.5). Fatal outcomes due to ILD and/or pneumonitis occurred in 0.9% of patients treated with ENHERTU.

ENHERTU in Combination with Pertuzumab In patients treated with ENHERTU 5.4 mg/kg in combination with pertuzumab (N=431), ILD occurred in 12% of patients. Median time to first onset was 8.0 months (range: 0.6 to 33.8). Fatal outcomes due to ILD and/or pneumonitis occurred in 0.5% of patients treated with ENHERTU in combination with pertuzumab.

ENHERTU followed by THP In patients treated with ENHERTU 5.4 mg/kg followed by THP in DESTINY-Breast11, ILD occurred in 4.4% of patients. Median time to first onset was 2.7 months (range: 1.1 to 6.0). Fatal outcomes due to ILD and/or pneumonitis occurred in one patient (0.3%) treated with ENHERTU followed by THP. HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg) In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, ILD occurred in 10% of patients.

Median time to first onset was 2.8 months (range: 1.2 to 21).

5.2 Neutropenia

5.2 Neutropenia Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. Based on the severity of neutropenia, ENHERTU may require dose interruption or reduction [see Dosage and Administration (2.3)].

HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ENHERTU as Monotherapy In patients treated with ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 65% of patients. Nineteen percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 22 days (range: 2 to 939).

Febrile neutropenia was reported in 1% of patients. ENHERTU in Combination with Pertuzumab In patients treated with ENHERTU 5.4 mg/kg in combination with pertuzumab (N=431), decreased neutrophil count occurred in 79% of patients. Median time to first onset was 22 days (range: 5 to 994). Twenty-nine percent had Grades 3 or 4 decreased neutrophil count.

Febrile neutropenia was reported in 2.6% of patients. ENHERTU followed by THP In patients treated with ENHERTU 5.4 mg/kg followed by THP in DESTINY-Breast11, a decrease in neutrophil count was reported in 58% of patients. Seventeen percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 42 days (range: 11 to 165).

Febrile neutropenia was reported in 0.9% of patients. HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg) In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, a decrease in neutrophil count was reported in 72% of patients. Fifty-one percent had Grade 3 or 4 decreased neutrophil count.

Median time to first onset of decreased neutrophil count was 16 days (range: 4 to 187). Febrile neutropenia was reported in 4.8% of patients.

5.3 Left Ventricular Dysfunction

5.3 Left Ventricular Dysfunction Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular dysfunction (LVD) has been observed with anti-HER2 therapies, including ENHERTU. Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated.

Manage LVD through treatment interruption. Permanently discontinue ENHERTU if LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure (CHF) [see Dosage and Administration (2.3)]. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment.

HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ENHERTU as Monotherapy In patients treated with ENHERTU 5.4 mg/kg, LVD was reported in 4.6% of patients, of which 0.6% were Grade 3 or 4. ENHERTU in Combination with Pertuzumab In patients treated with ENHERTU 5.4 mg/kg in combination with pertuzumab (N=431), LVEF decrease was reported in 11% of patients, of which 2.1% were Grade 3 or 4.

ENHERTU followed by THP In patients treated with ENHERTU 5.4 mg/kg followed by THP in DESTINY-Breast11, LVD was reported in 1.3% of patients, of which 0.3% were Grade 3. HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg) In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, no clinical adverse events of heart failure were reported; however, on echocardiography, 8% were found to have asymptomatic Grade 2 decrease in LVEF.

5.4 Embryo-Fetal Toxicity

5.4 Embryo-Fetal Toxicity Based on its mechanism of action, ENHERTU can cause fetal harm when administered to a pregnant woman. In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death.

Based on its mechanism of action, the topoisomerase inhibitor component of ENHERTU, DXd, can also cause embryo-fetal harm when administered to a pregnant woman because it is genotoxic and targets actively dividing cells [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Advise patients of the potential risks to a fetus.

Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose of ENHERTU [see Use in Specific Populations (8.1, 8.3)].

Drug interactions

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

DXd is primarily metabolized by CYP3A4.

Drug Interaction Studies Clinical Studies No clinically significant differences in pharmacokinetics of fam-trastuzumab deruxtecan-nxki or DXd were observed when used concomitantly with itraconazole (strong CYP3A inhibitor) or ritonavir (strong CYP3A inhibitor and OATP inhibitor).

In Vitro Studies CYP450 Enzymes : DXd does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A nor induce CYP1A2, CYP2B6, or CYP3A.

Transporter Systems : DXd is not an inhibitor of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, P-gp, BCRP, or BSEP.

DXd is a substrate of OATP1B1, OATP1B3, MATE2-K, P-gp, MRP1, and BCRP.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.1)] Neutropenia [see Warnings and Precautions (5.2)] Left Ventricular Dysfunction [see Warnings and Precautions (5.3)] The most common adverse reactions (≥20%), including laboratory abnormalities, in patients with: HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and HER2-Positive (including IHC 3+) Solid Tumors are decreased white blood cell count, nausea, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, increased alanine aminotransferase, increased blood alkaline phosphatase, vomiting, alopecia, constipation, decreased blood potassium, decreased appetite, diarrhea, and musculoskeletal pain. (6.1) HER2-Positive Early Breast Cancer are decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, decreased white blood cell count, nausea, peripheral neuropathy, diarrhea, decreased neutrophil count, alopecia, fatigue, decreased lymphocyte count, rash, musculoskeletal pain, decreased blood potassium, constipation, vomiting, stomatitis, and decreased appetite.

(6.1) HER2-Positive Metastatic Breast Cancer in Combination with Pertuzumab are decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, nausea, increased alanine aminotransferase, diarrhea, increased aspartate aminotransferase, decreased lymphocyte count, decreased platelet count, increased blood alkaline phosphatase, decreased blood potassium, fatigue, alopecia, vomiting, upper respiratory tract infection, constipation, decreased appetite, decreased weight, COVID-19, musculoskeletal pain, increased blood bilirubin, and abdominal pain. (6.1) HER2-Positive Gastric Cancer are decreased hemoglobin, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, nausea, decreased appetite, increased aspartate aminotransferase, fatigue, increased blood alkaline phosphatase, increased alanine aminotransferase, diarrhea, decreased blood potassium, vomiting, constipation, increased blood bilirubin, pyrexia, and alopecia.

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ENHERTU as Monotherapy The pooled safety population described in WARNINGS and PRECAUTIONS reflects exposure to ENHERTU 5.4 mg/kg intravenously every 3 weeks in 2233 patients in Study DS8201-A-J101 (NCT02564900), DESTINY-Breast01, DESTINY-Breast02, DESTINY-Breast03, DESTINY-Breast04, DESTINY-Breast06, DESTINY-Lung01, DESTINY-Lung02, DESTINY-CRC02, and DESTINY-PanTumor02.

Among these patients, 67% were exposed for greater than 6 months and 39% were exposed for greater than 12 months. In this pooled safety population, the most common (≥20%) adverse reactions (including laboratory abnormalities) were decreased white blood cell count (73%), nausea (72%), decreased hemoglobin (67%), decreased neutrophil count (65%), decreased lymphocyte count (60%), fatigue (55%), decreased platelet count (48%), increased aspartate aminotransferase (46%), increased alanine aminotransferase (43%), increased blood alkaline phosphatase (39%), vomiting (38%), alopecia (37%), constipation (32%), decreased blood potassium (32%), decreased appetite (31%), diarrhea (30%), and musculoskeletal pain (24%).

ENHERTU in Combination with Pertuzumab The pooled safety population described in WARNINGS and PRECAUTIONS reflects exposure to ENHERTU 5.4 mg/kg in combination with pertuzumab intravenously every 3 weeks in 431 patients in DESTINY-Breast07 (n=50), and DESTINY-Breast09 (n=381). Among these patients, 86% were exposed for greater than 6 months and 73% were exposed for greater than 12 months.

In this pooled safety population, the most common (≥20%) adverse reactions (including laboratory abnormalities) were decreased white blood cell count (86%), decreased hemoglobin (80%), decreased neutrophil count (79%), nausea (74%), increased alanine aminotransferase (65%), diarrhea (64%), increased aspartate aminotransferase (63%), decreased lymphocyte count (61%), decreased platelet count (55%), increased blood alkaline phosphatase (54%), decreased blood potassium (54%), fatigue (53%), alopecia (48%), vomiting (46%), upper respiratory tract infection (32%), constipation (31%), decreased appetite (31%), decreased weight (28%), musculoskeletal pain (23%), increased blood bilirubin (23%), and abdominal pain (22%). ENHERTU followed by THP The data described in the WARNINGS and PRECAUTIONS reflect exposure to ENHERTU 5.4 mg/kg intravenously every 3 weeks for four cycles followed by THP for four cycles in 320 patients in Study DESTINY-Breast11.

HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg) The data described in WARNINGS and PRECAUTIONS reflect exposure to ENHERTU 6.4 mg/kg intravenously every 3 weeks in 125 patients in DESTINY-Gastric01. HER2-Positive Early Breast Cancer DESTINY-Breast11 The safety of ENHERTU followed by THP was evaluated in 320 patients with HER2-positive (IHC 3+ or ISH+) early breast cancer who received at least one dose of ENHERTU 5.4 mg/kg followed by THP in DESTINY-Breast11 [see Clinical Studies (14.1)].

ENHERTU was administered by intravenous infusion once every three weeks for four cycles followed by THP for four cycles. The median duration of treatment was 5.6 months (range: 0.7 to 9.1) for patients who received ENHERTU followed by THP. Serious adverse reactions occurred in 11% of patients receiving ENHERTU followed by THP, including COVID-19 (0.9%) and ILD/pneumonitis (0.6%).

Fatal adverse reactions occurred in 0.6% of patients, including ILD/pneumonitis and death not otherwise specified (one patient each). In patients treated with ENHERTU followed by THP, the permanent discontinuation of ENHERTU due to adverse reactions occurred in 1.3%, of which ILD/pneumonitis accounted for 0.6%. Dose interruptions of ENHERTU due to adverse reactions occurred in 11% of patients.

The most frequent adverse reactions (>2%) associated with dose interruption were decreased neutrophil count and COVID-19. Dose reductions of ENHERTU occurred in 2.5% of patients treated with ENHERTU. The most common (≥20%) adverse reactions in patients treated with ENHERTU followed by THP, including laboratory abnormalities, were decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, decreased white blood cell count, nausea, peripheral neuropathy, diarrhea, decreased neutrophil count, alopecia, fatigue, decreased lymphocyte count, rash, musculoskeletal pain, decreased blood potassium, constipation, vomiting, stomatitis, and decreased appetite.

Tables 4 and 5 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast11. Table 4: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) Patients in DESTINY-Breast11 Adverse Reactions ENHERTU 5.4 mg/kg followed by THP N = 320 ddAC followed by THP N = 312 All Grades % Grade 3 or 4 % All Grades % Grade 3 or 4 % THP= paclitaxel, trastuzumab, and pertuzumab; ddAC=dose dense doxorubicin and cyclophosphamide; Events were graded using NCI CTCAE version 5.0.

Gastrointestinal Disorders Nausea 65 1.9 52 0.3 Diarrhea 59 6 54 3.2 Constipation 29 0.3 24 0 Vomiting 29 0.9 21 0.6 Stomatitis Including aphthous ulcer, cheilitis, glossitis, mouth ulceration, mucosal inflammation, and stomatitis. 23 0.3 36 1.0 Abdominal pain Including abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and gastrointestinal pain. 16 0 12 0 Nervous System Disorders Peripheral neuropathy Including dysesthesia, hypoesthesia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy. 59 2.5 47 2.2 Headache Including headache, migraine, and sinus headache. 18 0 16 0 Skin and Subcutaneous Tissue Disorders Alopecia 48 0 49 0 Rash Including dermatitis, dermatitis acneiform, dermatitis bullous, eczema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, skin exfoliation, and urticarial dermatitis. 31 0.9 25 1.0 General Disorders and Administration Site Conditions Fatigue Including asthenia, fatigue, and malaise. 41 0.6 55 2.2 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including arthralgia, back pain, bone pain, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and pain in extremity. 30 0 28 0.3 Metabolism and Nutrition Disorders Decreased appetite 20 0 18 0.3 Respiratory, Thoracic and Mediastinal Disorders Epistaxis 15 0 10 0 Cough 10 0 14 0 Infections and Infestations Upper respiratory tract infection Including influenza, influenza-like illness, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection. 13 0.6 20 0.3 COVID-19 10 0.9 11 0.3 Other clinically relevant adverse reactions reported in less than 10% of patients in the ENHERTU followed by THP treated group were: General disorders and administration site conditions: peripheral edema (9%), pyrexia (8%), mucosal inflammation (1.9%) Nervous System Disorders: dysgeusia (9%), dizziness (4.7%) Eye Disorders: dry eye (8%), blurred vision (6%) [including vision blurred, visual impairment] Gastrointestinal disorders: dyspepsia (8%), gastritis (3.4%), abdominal distension (2.5%), flatulence (0.9%) Respiratory, Thoracic, and Mediastinal Disorders: dyspnea (7%), ILD (4.4%) [including interstitial lung disease, lung opacity, pneumonia fungal, pneumonitis]. Skin and Subcutaneous Tissue Disorders: pruritus (6%) and skin hyperpigmentation (1.6%) [including skin hyperpigmentation and skin discoloration] Injury, Poisoning, and Procedural Complications: infusion-related reactions (4.7%) Investigations: decreased weight (3.4%) Blood and Lymphatic System Disorders: febrile neutropenia (0.9%) Metabolism and Nutrition Disorders: dehydration (0.3%) Table 5: Selected Laboratory Abnormalities in Patients in DESTINY-Breast11 Laboratory Parameter ENHERTU 5.4 mg/kg followed by THP N=320 ddAC followed by THP N = 312 All Grades % Grades 3-4 % All Grades % Grades 3-4 % THP= paclitaxel, trastuzumab, and pertuzumab; ddAC= dose dense doxorubicin and cyclophosphamide Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.

Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities. Hematology Decreased hemoglobin 83 2.2 97 10 Decreased white blood cell count 67 8 87 31 Decreased neutrophil count 58 17 66 38 Decreased lymphocyte count 40 3.1 93 39 Decreased platelet count 8 0.9 28 2.9 Chemistry Increased alanine aminotransferase 79 5 77 4.2 Increased aspartate aminotransferase 74 2.5 68 1 Decreased blood potassium 29 4.1 25 4.5 Increased blood alkaline phosphatase 19 0 24 0 Decreased sodium 19 1.9 23 2.6 Increased blood creatinine 8 0.6 8 1.3 Increased blood bilirubin 7 0 4.2 0.6 DESTINY-Breast05 The safety of ENHERTU was evaluated in 806 patients with HER2-positive breast cancer with residual invasive disease following neoadjuvant HER2-targeted therapy who then received at least one dose of ENHERTU 5.4 mg/kg [see Clinical Studies (14.1)].

ENHERTU was administered by intravenous infusion once every three weeks for 14 cycles. The median duration of treatment was 10 months (range: 0.7 to 16) for patients who received ENHERTU. Serious adverse reactions occurred in 17% of patients receiving ENHERTU. Serious adverse reactions in ≥1% of patients who received ENHERTU were ILD/pneumonitis, radiation pneumonitis, pneumonia, and platelet count decreased.

Fatal adverse reactions occurred in 0.4% of patients including ILD/pneumonitis (2 patients) and respiratory tract infection (one patient). Permanent discontinuation of ENHERTU due to an adverse reaction occurred in 18% of patients. The adverse reaction which resulted in permanent discontinuation of ENHERTU >2% included ILD/pneumonitis.

Dose interruptions of ENHERTU due to an adverse reaction occurred in 50% of patients. Adverse reactions which required dosage interruptions in >2% included radiation pneumonitis, neutrophil count decreased, COVID-19, white blood cell count decreased, ILD/pneumonitis, platelet count decreased, upper respiratory tract infection, fatigue, cough, and pyrexia.

Dose reductions of ENHERTU due to an adverse reaction occurred in 26% of patients. Adverse reactions which required dose reductions in >2% of patients included nausea, fatigue, platelet count decreased, ILD/pneumonitis, and neutrophil count decreased. The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count, decreased lymphocyte count, decreased neutrophil count, nausea, decreased hemoglobin, increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, decreased platelet count, increased blood alkaline phosphatase, constipation, vomiting, decreased blood potassium, diarrhea, musculoskeletal pain, and decreased appetite.

Tables 6 and 7 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast05. Table 6: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3-4) in Patients Treated with ENHERTU in DESTINY-Breast05 Adverse Reactions ENHERTU 5.4 mg/kg N= 806 Ado-Trastuzumab Emtansine (T-DM1) 3.6mg/kg N=801 All Grades % Grade 3 or 4 % All Grades % Grades 3 or 4 % Events were graded using NCI CTCAE version 5.0.

Gastrointestinal Disorders Nausea 71 4.5 29 0.1 Constipation 32 0 16 0.1 Vomiting 31 1.1 9 0.1 Diarrhea 23 1.2 9 0.4 Abdominal pain Including abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and gastrointestinal pain. 15 0.2 9 0.1 Stomatitis Including aphthous ulcer, cheilitis, mouth ulceration, mucosal inflammation, pharyngeal inflammation, and stomatitis. 10 0.2 6 0.1 General Disorders and Administration Site Conditions Fatigue Including asthenia, fatigue, lethargy, and malaise. 54 6 37 1.0 Pyrexia 10 0.1 12 0.2 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including arthralgia, back pain, bone pain, limb discomfort, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and pain in extremity. 23 0.7 32 0.6 Metabolism and Nutrition Disorders Decreased appetite 20 0.9 10 0 Infections and Infestations Upper respiratory tract infection Including influenza, influenza like illness, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection. 18 0.1 17 0.5 COVID-19 17 0.5 20 0.4 Respiratory, Thoracic and Mediastinal Disorders Interstitial lung disease Including COVID-19 pneumonia, interstitial lung disease, lung opacity, organizing pneumonia, pneumocystis jirovecii pneumonia, pneumonia, and pneumonitis which was adjudicated as ILD (irrespective of causality). Adjudicated drug-related ILD for ENHERTU was 10% for all Grades and 0.9% for Grades 3 or 4 and for T-DM1, 1.6% for all Grades and 0% for Grades 3 or 4. 17 1.1 3.7 0.2 Cough 13 0 11 0 Nervous System Disorders Headache Including headache, migraine, and sinus headache. 16 0.2 21 0.1 Peripheral neuropathy Including dysesthesia, hyperesthesia, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy. 13 0.4 20 1.1 Dizziness Including dizziness, dizziness postural, vertigo, and vertigo positional. 11 0.4 7 0.1 Skin and Subcutaneous Tissue Disorders Alopecia 16 0 1.2 0 Rash Including dermatitis, dermatitis acneiform, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema, eczema asteatotic, erythema multiforme, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, skin exfoliation, and Stevens-Johnson syndrome. 10 0.4 14 0.1 Investigations Decreased weight 12 0.2 7 0.1 Other clinically relevant adverse reactions reported in less than 10% of patients in the ENHERTU-treated group were: Gastrointestinal disorders: dyspepsia (8%), gastritis (2.5%), abdominal distension (1.7%), flatulence (1.5%) Respiratory, Thoracic, and Mediastinal Disorders: dyspnea (4.5%), epistaxis (3.8%) Skin and Subcutaneous Tissue Disorders: pruritus (4.2%), skin hyperpigmentation (3.5%) [including pigmentation disorder, skin discoloration, skin hyperpigmentation] Nervous System Disorders: dysgeusia (3.7%) Eye Disorders: dry eye (2.7%), vision blurred (2.7%) [including vision blurred, visual impairment] Metabolism and Nutrition Disorders: dehydration (1%) Injury, Poisoning, and Procedural Complications: infusion related reaction (0.7%) [including hypersensitivity, infusion related reaction] Blood and Lymphatic System Disorders: febrile neutropenia (0.5%) Table 7: Selected Laboratory Abnormalities in Patients in DESTINY-Breast05 Laboratory Parameter ENHERTU 5.4 mg/kg N=806 Ado-Trastuzumab Emtansine (T-DM1) 3.6mg/kg N = 801 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.

Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities. Hematology Decreased white blood cell count 80 17 46 2.3 Decreased lymphocyte count 72 35 54 17 Decreased neutrophil count 72 23 38 4.9 Decreased hemoglobin 61 2.9 36 2 Decreased platelet count 46 8 93 33 Chemistry Increased aspartate aminotransferase 60 1 91 4.3 Increased alanine aminotransferase 53 1 80 4.2 Increased blood alkaline phosphatase 39 0 53 0.1 Decreased blood potassium 27 1.7 44 2.1 Increased blood creatinine 13 0.2 9 0.1 Increased blood bilirubin 9 0 20 0 Radiotherapy-Related Pneumonitis and Skin Injury in the Post Neoadjuvant Early Breast Cancer Setting Among patients receiving sequential or concurrent adjuvant radiotherapy in DESTINY-Breast05, radiation pneumonitis occurred in 31% of patients receiving ENHERTU 5.4 mg/kg (N=757) and 31% of patients receiving ado-trastuzumab emtansine (T-DM1) 3.6 mg/kg (N=750), as reported by the investigator.

All cases of patients receiving ENHERTU and adjuvant radiotherapy (ART) were either Grade 1 (27%) or Grade 2 (4.9%). Similarly, all cases of patients receiving T-DM1 and ART were either Grade 1 (24%) or Grade 2 (7%). A higher incidence of radiation pneumonitis was reported for patients who received sequential vs. concurrent ART, irrespective of treatment arm: 34% for ENHERTU vs. 37% for T-DM1, respectively, with sequential ART and 29% vs. 27%, respectively, with concurrent ART.

For patients treated with ENHERTU, median time to onset of first event of radiation pneumonitis was 4.1 months (range: 1.3 – 11.6 months). Among patients receiving ART and ENHERTU, radiation skin injury occurred in 20% of all patients, of which 1.6% were Grade 3 and none were Grade 4. Among patients receiving ART and T-DM1, radiation skin injury occurred in 18% of all patients, of which 0.4% were Grade 3 and none were Grade 4.

HER2-Positive Metastatic Breast Cancer DESTINY-Breast09 The safety of ENHERTU 5.4 mg/kg in combination with pertuzumab was evaluated in DESTINY-Breast09, a randomized, three-arm, multicenter study including 763 patients with HER2-positive (IHC 3+ or ISH+) unresectable or metastatic breast cancer [see Clinical Studies (14.2)]. Three hundred eighty-one patients received ENHERTU in combination with pertuzumab and 382 patients received THP (taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab).

Among patients who received ENHERTU in combination with pertuzumab, the median duration of treatment was 22 months (range: 0.3 months to 44.5 months). Serious adverse reactions occurred in 27% of patients receiving ENHERTU in combination with pertuzumab. Serious adverse reactions in >1% of patients were diarrhea, pneumonia, febrile neutropenia, hypokalemia, vomiting, ILD, pulmonary embolism, and sepsis.

Fatalities due to adverse reactions occurred in 3.4% of patients including pneumonia (n=3), ILD (n=2), sepsis (n=2), pulmonary embolism, septic shock, acute kidney injury, dyspnea, febrile neutropenia, and intestinal ischemia (one patient each). ENHERTU was discontinued for adverse reactions in 21% of patients. The most frequent adverse reactions (>2%) associated with permanent discontinuation was ILD/pneumonitis (6%).

Dose interruptions due to adverse reactions occurred in 69% of patients. The most frequent adverse reactions (>2%) associated with dose interruption were COVID-19, neutropenia, upper respiratory tract infection, fatigue, anemia, hypokalemia, ILD/pneumonitis, thrombocytopenia, pneumonia, diarrhea, transaminase increased, leukopenia, cough, pyrexia, decreased appetite, and blood bilirubin increased.

Dose reductions occurred in 46% of patients treated with ENHERTU in combination with pertuzumab. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, neutropenia, nausea, diarrhea, ILD/pneumonitis, thrombocytopenia, vomiting, transaminases increased, decreased weight, febrile neutropenia, and hypokalemia.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, nausea, increased alanine aminotransferase, diarrhea, increased aspartate aminotransferase decreased lymphocyte count, decreased platelet count, increased blood alkaline phosphatase, decreased blood potassium, fatigue, alopecia, vomiting, upper respiratory tract infection, constipation, decreased appetite, decreased weight, COVID-19, musculoskeletal pain, increased blood bilirubin, and abdominal pain. Tables 8 and 9 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast09.

Table 8: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients Treated with ENHERTU in Combination with Pertuzumab in DESTINY-Breast09 Adverse Reactions ENHERTU 5.4 mg/kg + Pertuzumab N= 381 THP THP=taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab N=382 All Grades % Grade 3-4 % All Grades % Grades 3-4 % Gastrointestinal Disorders Nausea 75 5 34 0.3 Diarrhea 64 8 62 6 Vomiting 46 2.4 18 0.5 Constipation 33 0.3 12 0 Abdominal pain Including abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and gastrointestinal pain. 23 0.3 13 0 Stomatitis Including aphthous ulcer, mouth ulceration, oral mucosal eruption, and stomatitis. 16 1.3 17 1.3 Dyspepsia 12 0 6 0 General Disorders and Administration Site Conditions Fatigue Including asthenia, fatigue, lethargy, and malaise. 53 8 42 2.1 Pyrexia 16 0 18 1.0 Skin and Subcutaneous Tissue Disorders Alopecia 48 0 53 0.5 Rash Including rash, rash macular, rash maculo-papular, rash pruritic, and rash pustular. 17 0.3 22 0.3 Pruritus 11 0 11 0.3 Infections and Infestations Upper respiratory tract infection Including Influenza, Influenza like illness, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection. 33 1.6 30 0.5 COVID-19 28 0.3 22 0.3 Metabolism and Nutrition Disorders Decreased appetite 32 2.4 18 0.8 Hypoalbuminemia 11 0.3 8 0.3 Investigations Decreased weight 30 3.1 11 0.8 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including back pain, bone pain, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and pain in extremity. 24 1 33 0.3 Nervous System Disorders Headache Including headache and migraine. 19 0.3 14 0 Dysgeusia 13 0 9 0 Dizziness 12 0.3 10 0 Respiratory, Thoracic, and Mediastinal Disorders Cough 17 0.3 13 0 Interstitial lung disease Interstitial lung disease includes chronic obstructive pulmonary disease (n=1), interstitial lung disease (n=23), pneumonia (n=3), and pneumonitis (n=22). These events were adjudicated as ILD and related to use of ENHERTU 12 0 1 0 Eye Disorders Dry eye 11 0 6 0 Other clinically relevant adverse reactions reported in less than 10% of patients treated with ENHERTU in combination with pertuzumab were: Blood and Lymphatic System Disorders: febrile neutropenia (2.9%) Eye Disorders: blurred vision (4.2%) Gastrointestinal Disorders: abdominal distension (6%), gastritis (3.9%), flatulence (2.4%) General Disorders and Administration Site Conditions: mucosal inflammation (9%) Injury, poisoning, and procedural complications: infusion related reactions (2.6%) [including hypersensitivity and infusion-related reactions] Metabolism and Nutrition Disorders: dehydration (2.9%) Respiratory, Thoracic, and Mediastinal Disorders: epistaxis (8%), dyspnea (6%) Skin and Subcutaneous Tissue Disorders: dry skin (7%), skin hyperpigmentation (6%) [including skin hyperpigmentation, skin discoloration, and pigmentation disorder] Table 9: Selected Laboratory Abnormalities in Patients in DESTINY-Breast09 Laboratory Parameter ENHERTU 5.4 mg/kg + Pertuzumab N= 381 THP THP=taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab] N=382 All Grades % Grade 3-4 % All Grades % Grades 3-4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.

Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities. Hematology Decreased white blood cell count 87 11 82 31 Decreased hemoglobin 80 12 86 6 Decreased neutrophil count 78 29 66 40 Decreased lymphocyte count 62 14 58 11 Decreased platelet count 56 8 20 1.9 Chemistry Increased alanine aminotransferase 66 3.2 45 1.9 Increased aspartate aminotransferase 62 2.1 41 1.9 Increased blood alkaline phosphatase 55 0.3 36 0.3 Decreased blood potassium 54 20 29 6 Increased blood bilirubin 23 0.3 10 0.3 Increased blood creatinine 9 1.8 7 0.3 DESTINY-Breast03 The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast03 [see Clinical Studies (14.2)].

ENHERTU was administered by intravenous infusion once every three weeks. The median duration of treatment was 14 months (range: 0.7 to 30) for patients who received ENHERTU and 7 months (range: 0.7 to 25) for patients who received ado-trastuzumab emtansine. Serious adverse reactions occurred in 19% of patients receiving ENHERTU.

Serious adverse reactions in >1% of patients who received ENHERTU were vomiting, interstitial lung disease, pneumonia, pyrexia, and urinary tract infection. Fatalities due to adverse reactions occurred in 0.8% of patients including COVID-19 and sudden death (one patient each). ENHERTU was permanently discontinued in 14% of patients, of which ILD/pneumonitis accounted for 8%.

Dose interruptions due to adverse reactions occurred in 44% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, leukopenia, anemia, thrombocytopenia, pneumonia, nausea, fatigue, and ILD/pneumonitis. Dose reductions occurred in 21% of patients treated with ENHERTU.

The most frequent adverse reactions (>2%) associated with dose reduction were nausea, neutropenia, and fatigue. The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea, decreased white blood cell count, decreased neutrophil count, increased aspartate aminotransferase, decreased hemoglobin, decreased lymphocyte count, increased alanine aminotransferase, decreased platelet count, fatigue, vomiting, increased blood alkaline phosphatase, alopecia, decreased blood potassium, constipation, musculoskeletal pain, diarrhea, decreased appetite, headache, respiratory infection, abdominal pain, increased blood bilirubin, and stomatitis.

Tables 10 and 11 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast03. Table 10: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3-4) in Patients Treated with ENHERTU in DESTINY-Breast03 Adverse Reactions ENHERTU 5.4 mg/kg N=257 Ado-trastuzumab emtansine 3.6 mg/kg N=261 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Events were graded using NCI CTCAE version 5.0.

Gastrointestinal Disorders Nausea 76 7 30 0.4 Vomiting 49 1.6 10 0.8 Constipation 34 0 20 0 Diarrhea 29 1.2 7 0.4 Abdominal pain Including abdominal pain, abdominal discomfort, lower abdominal pain, and upper abdominal pain. 21 0.8 8 0.4 Stomatitis Including stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosal eruption. 20 0.8 5 0 Dyspepsia 11 0 6 0 General Disorders and Administration Site Conditions Fatigue Including fatigue, asthenia, malaise, and lethargy. 49 6 35 0.8 Skin and Subcutaneous Tissue Disorders Alopecia This Grade 3 event was reported by the investigator. Per NCI CTCAE v.5.0, the highest NCI CTCAE grade for alopecia is Grade 2. 37 0.4 3.1 0 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain, and limb discomfort. 31 1.2 25 0.4 Metabolism and Nutrition Disorders Decreased appetite 29 1.6 17 0.4 Investigations Decreased weight 17 1.2 6 0.4 Respiratory, Thoracic, and Mediastinal Disorders Respiratory infection Including respiratory tract infection, lower and upper respiratory tract infection, pneumonia, influenza, influenza-like illness, viral upper respiratory infection, bronchitis, and respiratory syncytial virus infection. 22 0.8 12 1.1 Epistaxis 11 0 16 0.4 Cough 11 0.4 10 0 Interstitial lung disease Interstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU: pneumonitis, interstitial lung disease, organizing pneumonia, pneumonia, and pulmonary mass.

For ado-trastuzumab emtansine: pneumonitis, interstitial lung disease, organizing pneumonia, and pulmonary embolism. 11 0.8 1.9 0 Nervous System Disorders Headache Including headache and migraine. 22 0.4 16 0 Peripheral neuropathy Including peripheral neuropathy, peripheral sensory neuropathy, and paresthesia. 13 0.4 14 0.4 Dizziness 13 0.4 8 0 Other clinically relevant adverse reactions reported in less than 10% of patients in the ENHERTU-treated group were: Respiratory, Thoracic, and Mediastinal Disorders: dyspnea (8%) Skin and Subcutaneous Tissue Disorders: pruritus (8%) and skin hyperpigmentation (6%) [including skin hyperpigmentation, skin discoloration, and pigmentation disorder] Nervous System Disorders: dysgeusia (6%) Metabolism and Nutrition Disorders: dehydration (4.3%) Eye Disorders: blurred vision (3.5%) Cardiac Disorders: asymptomatic left ventricular ejection fraction decrease (2.7%) [see Warnings and Precautions (5.3)] Injury, Poisoning, and Procedural Complications: infusion-related reactions (2.3%) [including hypersensitivity and infusion-related reactions] Blood and Lymphatic System Disorders: febrile neutropenia (0.8%) Table 11: Selected Laboratory Abnormalities in Patients in DESTINY-Breast03 Laboratory Parameter ENHERTU 5.4 mg/kg N=257 Ado-trastuzumab emtansine 3.6 mg/kg N=261 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.

Hematology Decreased white blood cell count 74 8 24 0.8 Decreased neutrophil count 70 18 30 2.3 Decreased hemoglobin 64 7 38 6 Decreased lymphocyte count 55 14 23 3.9 Decreased platelet count 52 7 79 24 Chemistry Increased aspartate aminotransferase 67 0.8 83 5 Increased alanine aminotransferase 53 1.6 67 6 Increased blood alkaline phosphatase 49 0.8 46 0.8 Decreased blood potassium 35 4.7 39 1.5 Increased blood bilirubin 20 0 14 0 Increased blood creatinine 16 0.8 8 0.4 DESTINY-Breast02 The safety of ENHERTU was evaluated in 404 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast02 [see Clinical Studies (14.2)]. ENHERTU was administered by intravenous infusion once every three weeks.

The median duration of treatment was 11 months (range: 0.7 to 45) for patients who received ENHERTU. Serious adverse reactions occurred in 26% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were COVID-19, ILD, pneumonia, vomiting, fatigue, and nausea. Fatalities due to adverse reactions occurred in 2.5% of patients including pneumonitis (2 patients), acute myeloid leukemia, brain edema, COVID-19, hemorrhage, hepatitis B, malignant pleural effusion, pneumonia, and vasogenic cerebral edema (one patient each).

ENHERTU was permanently discontinued in 20% of patients, of which ILD accounted for 9%. Dose interruptions due to adverse reactions occurred in 45% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, COVID-19, anemia, fatigue, leukopenia, upper respiratory tract infection, and thrombocytopenia.

Dose reductions occurred in 25% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, neutropenia, and vomiting. The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, fatigue, decreased lymphocyte count, decreased platelet count, increased alanine aminotransferase, vomiting, increased aspartate aminotransferase, alopecia, increased blood alkaline phosphatase, constipation, decreased appetite, decreased blood potassium, diarrhea, musculoskeletal pain, increased blood bilirubin, abdominal pain, and headache.

Tables 12 and 13 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast02. Table 12: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3-4) in Patients Treated with ENHERTU in DESTINY-Breast02 Adverse Reactions ENHERTU 5.4 mg/kg N=404 Treatment of Physician's Choice N=195 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Events were graded using NCI CTCAE version 5.0.

Gastrointestinal Disorders Nausea 73 7 37 2.6 Vomiting 38 3.7 13 1 Constipation 35 0.3 11 0.5 Diarrhea 27 2.7 54 7 Abdominal pain Including abdominal discomfort, abdominal pain, upper abdominal pain, lower abdominal pain, and gastrointestinal pain 22 1 20 2.1 Dyspepsia 12 0 9 0 Stomatitis Including aphthous ulcer, mouth ulceration, and stomatitis 12 1 21 1 General Disorders and Administration Site Conditions Fatigue Including asthenia, fatigue, lethargy, and malaise 62 9 37 1 Skin and Subcutaneous Tissue Disorders Alopecia 37 0.3 4.1 0 Metabolism and Nutrition Disorders Decreased appetite 31 1.7 18 0.5 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including back pain, bone pain, limb discomfort, musculoskeletal chest pain, musculoskeletal pain, muscle spasms, myalgia, neck pain, and pain in extremity 25 0.7 18 0.5 Nervous System Disorders Headache Including headache and migraine 20 0.3 6 0 Investigations Decreased weight 18 0.3 3.6 0 Respiratory, Thoracic, and Mediastinal Disorders Cough 13 0 10 0 Interstitial lung disease Interstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU: pneumonitis, interstitial lung disease, idiopathic interstitial pneumonia, lung disorder, pulmonary toxicity, and pneumonia. 10 0.7 0.5 0.5 Other clinically relevant adverse reactions reported in less than 10% of patients in the ENHERTU-treated group were: Respiratory, Thoracic, and Mediastinal Disorders: dyspnea (8%) and epistaxis (8%) Skin and Subcutaneous Tissue Disorders: rash (8%) [including rash, pustular rash, maculo-papular rash, and pruritic rash], pruritus (5%), skin hyperpigmentation (5%) [including skin hyperpigmentation and pigmentation disorder] Nervous System Disorders: dizziness (8%) and dysgeusia (8%) Cardiac Disorders: asymptomatic left ventricular ejection fraction decrease (4.2%) [see Warnings and Precautions (5.3)] Eye Disorders: dry eye (6%) and blurred vision [including blurred vision and visual impairment] (3%) Metabolism and Nutrition Disorders: dehydration (2.7%) Injury, Poisoning, and Procedural Complications: infusion-related reactions (1.2%) Blood and Lymphatic System Disorders: febrile neutropenia (0.3%) Table 13: Selected Laboratory Abnormalities in Patients in DESTINY-Breast02 Laboratory Parameter ENHERTU 5.4 mg/kg N=404 Treatment of Physician's Choice N=195 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.

Hematology Decreased white blood cell count 70 12 42 3.2 Decreased hemoglobin 67 9 54 3.2 Decreased neutrophil count 64 16 34 4.7 Decreased lymphocyte count 58 17 38 4.7 Decreased platelet count 48 2.7 31 1.6 Chemistry Increased alanine aminotransferase 43 1 32 1.6 Increased aspartate aminotransferase 37 0.7 29 2.1 Increased blood alkaline phosphatase 37 0 17 0 Decreased blood potassium 30 3.7 29 8 Increased blood bilirubin 23 0.3 44 2.1 Increased blood creatinine 7 0.3 13 0 DESTINY-Breast01 and Study DS8201-A-J101 The safety of ENHERTU was evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast01 and Study DS8201-A-J101 (NCT02564900) [see Clinical Studies (14.2)]. ENHERTU was administered by intravenous infusion once every three weeks.

The median duration of treatment was 7 months (range: 0.7 to 31). In the pooled 234 patients, the median age was 56 years (range: 28-96), 74% of patients were <65 years, 99.6% of patients were female, and the majority were White (51%) or Asian (42%). Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (58%) or 1 (42%) at baseline.

Ninety-four percent had visceral disease, 31% had bone metastases, and 13% had brain metastases. Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were interstitial lung disease, pneumonia, vomiting, nausea, cellulitis, decreased blood potassium, and intestinal obstruction.

Fatalities due to adverse reactions occurred in 4.3% of patients including interstitial lung disease (2.6%), and the following events occurred in one patient each (0.4%): acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemorrhagic shock. ENHERTU was permanently discontinued in 9% of patients, of which ILD accounted for 6%.

Dose interruptions due to adverse reactions occurred in 33% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, thrombocytopenia, leukopenia, upper respiratory tract infection, fatigue, nausea, and ILD. Dose reductions occurred in 18% of patients treated with ENHERTU.

The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, and neutropenia. The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, fatigue, vomiting, alopecia, increased aspartate aminotransferase, increased alanine aminotransferase, decreased platelet count, constipation, decreased appetite, diarrhea, decreased blood potassium, and cough.

Tables 14 and 15 summarize common adverse reactions and laboratory abnormalities observed in ENHERTU-treated patients in DESTINY-Breast01 and Study DS8201-A-J101. Table 14: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients in DESTINY-Breast01 and Study DS8201-A-J101 Adverse Reactions ENHERTU 5.4 mg/kg N=234 All Grades % Grades 3 or 4 % Events were graded using NCI CTCAE version 4.03.

Gastrointestinal Disorders Nausea 79 7 Vomiting 47 3.8 Constipation 35 0.9 Diarrhea 29 1.7 Abdominal pain Including abdominal discomfort, gastrointestinal pain, abdominal pain, lower abdominal pain, and upper abdominal pain 19 1.3 Stomatitis Including stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosa blistering. One Grade 1 event of aphthous ulcer was not included in the summary of grouped term stomatitis (from DESTINY-Breast01). 14 0.9 Dyspepsia 12 0 General Disorders and Administration Site Conditions Fatigue Including fatigue and asthenia 59 6 Skin and Subcutaneous Tissue Disorders Alopecia 46 0.4 This Grade 3 event was reported by the investigator.

Per NCI CTCAE v.4.03, the highest NCI CTCAE grade for alopecia is Grade 2. Rash Including rash, pustular rash, and maculo-papular rash 10 0 Metabolism and Nutrition Disorders Decreased appetite 32 1.3 Respiratory, Thoracic, and Mediastinal Disorders Cough 20 0 Dyspnea 13 1.3 Epistaxis 13 0 Interstitial lung disease Interstitial lung disease includes events that were adjudicated as drug-induced ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, and alveolitis. 9 2.6 All events had fatal outcomes (n=6).

Nervous System Disorders Headache Including headache, sinus headache, and migraine 19 0 Dizziness 10 0 Infections and Infestations Upper respiratory tract infection Including influenza, influenza-like illness, and upper respiratory tract infection 15 0 Eye Disorders Dry eye 11 0.4 This Grade 4 event was reported by the investigator. Per NCI CTCAE v.4.03, the highest NCI CTCAE grade for dry eye is Grade 3.

Other clinically relevant adverse reactions reported in less than 10% of patients were: Injury, Poisoning, and Procedural Complications: infusion-related reactions (2.6%) Blood and Lymphatic System Disorders: febrile neutropenia (1.7%) Table 15: Selected Laboratory Abnormalities in Patients with Unresectable or Metastatic HER2-positive Breast Cancer Treated with ENHERTU in DESTINY-Breast01 and Study DS8201-A-J101 Laboratory Parameter ENHERTU 5.4 mg/kg N=234 All Grades % Grades 3 or 4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.4.03 grade-derived laboratory abnormalities.

Hematology Decreased white blood cell count 70 7 Decreased hemoglobin 70 7 Decreased neutrophil count 62 16 Decreased platelet count 37 3.4 Chemistry Increased aspartate aminotransferase 41 0.9 Increased alanine aminotransferase 38 0.4 Decreased blood potassium 26 3 HER2-Low and HER2-Ultralow Metastatic Breast Cancer DESTINY-Breast06 The safety of ENHERTU was evaluated in 434 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who received ENHERTU 5.4 mg/kg in DESTINY-Breast06 [see Clinical Studies (14.3)]. ENHERTU was administered by intravenous infusion once every three weeks.

The median duration of treatment was 11 months (range: 0.4 to 39.6) for patients who received ENHERTU. Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were interstitial lung disease (ILD)/pneumonitis, COVID-19, febrile neutropenia, and hypokalemia.

Fatalities due to adverse reactions occurred in 2.8% of patients including ILD (0.7%); sepsis (0.5%); and COVID-19 pneumonia, bacterial meningoencephalitis, neutropenic sepsis, peritonitis, cerebrovascular accident, general physical health deterioration (0.2% each). ENHERTU was permanently discontinued in 14% of patients.

The most frequent adverse reactions (>2%) associated with permanent discontinuation was ILD/pneumonitis. Dose interruptions due to adverse reactions occurred in 48% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were COVID-19, decreased neutrophil count, anemia, pyrexia, pneumonia, decreased white blood cell count, and ILD.

Dose reductions occurred in 25% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were nausea, fatigue, decreased platelet count, and decreased neutrophil count. The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count, decreased neutrophil count, nausea, decreased hemoglobin, decreased lymphocyte count, fatigue, decreased platelet count, alopecia, increased alanine aminotransferase, increased blood alkaline phosphatase, increased aspartate aminotransferase, decreased blood potassium, diarrhea, vomiting, constipation, decreased appetite, COVID-19, and musculoskeletal pain.

Tables 16 and 17 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast06. Table 16: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients Treated with ENHERTU in DESTINY-Breast06 Adverse Reactions ENHERTU 5.4 mg/kg Chemotherapy N=434 N=417 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Events were graded using NCI CTCAE version 5.0.

Gastrointestinal Disorders Nausea 70 2.1 30 0.5 Diarrhea 34 2.3 27 2.6 Vomiting 34 1.4 12 0.2 Constipation 32 0.7 15 0.5 Abdominal pain Including abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and gastrointestinal pain. 20 0.5 14 0.2 Stomatitis Including stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, oral mucosal blistering, and oral mucosal eruption. 15 0 11 0.5 Dyspepsia 12 0 4.8 0 General Disorders and Administration Site Conditions Fatigue Including fatigue, asthenia, malaise, and lethargy. 53 4.4 40 2.4 Pyrexia 12 0.2 7 0 Skin and Subcutaneous Tissue Disorders Alopecia 48 0 21 0.5 Rash Including dermatitis, dermatitis allergic, dermatitis contact, eczema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, and rash pustular. 12 0.2 43 8 Metabolism and Nutrition Disorders Decreased appetite 26 1.4 12 0.5 Infections and Infestations COVID-19 Including COVID-19, COVID-19 pneumonia. 26 0.9 13 1 Upper respiratory tract infection Including influenza, influenza-like illness, upper respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, rhinitis, and laryngitis. 19 0 9 0 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain, and limb discomfort. 24 0.5 23 1.9 Nervous System Disorders Headache Including migraine, headache, and sinus headache. 18 0.5 10 0 Dysgeusia 12 0.2 6 0 Respiratory, Thoracic, and Mediastinal Disorders Cough 16 0 9 0 Interstitial lung disease Including bronchiectasis, interstitial lung disease, lower respiratory tract infection, pneumonia, pneumonia bacterial, pneumonitis, and pulmonary toxicity. 11 0.7 0.2 0 Epistaxis 10 0 3.6 0.2 Other clinically relevant adverse reactions reported in less than 10% of patients in the ENHERTU-treated group were: Nervous System Disorders: dizziness (9%) Investigations: decreased weight (7%) Eye Disorders: dry eye (7%), and blurred vision (5%) Respiratory, Thoracic, and Mediastinal Disorders: dyspnea (6%) Gastrointestinal Disorders: abdominal distension (4.8%), flatulence (2.3%), and gastritis (0.7%) Skin and Subcutaneous Tissue Disorders: pruritus (3.9%), and skin hyperpigmentation (0.9%) Metabolism and Nutrition Disorders: dehydration (1.6%) Blood and lymphatic system disorders: febrile neutropenia (1.2%) Injury, Poisoning, and Procedural Complications: infusion related reaction (1.2%) Table 17: Selected Laboratory Abnormalities in Patients in DESTINY-Breast06 Laboratory Parameter ENHERTU 5.4 mg/kg Chemotherapy N=434 N=417 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.

Hematology Decreased white blood cell count 86 13 71 11 Decreased neutrophil count 75 27 53 20 Decreased hemoglobin 69 9 58 5 Decreased lymphocyte count 66 19 46 8 Decreased platelet count 48 6 25 1 Chemistry Increased alanine aminotransferase 44 3.2 30 0.7 Increased blood alkaline phosphatase 43 0.2 22 0.2 Increased aspartate aminotransferase 41 2.6 27 1.2 Decreased blood potassium 35 8 15 2.9 Increased blood bilirubin 16 1.9 23 1.5 Increased blood creatinine 10 1.9 8 1 DESTINY-Breast04 The safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who received ENHERTU 5.4 mg/kg in DESTINY-Breast04 [see Clinical Studies (14.3)]. ENHERTU was administered by intravenous infusion once every three weeks.

The median duration of treatment was 8 months (range: 0.2 to 33) for patients who received ENHERTU. Serious adverse reactions occurred in 28% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, pneumonia, dyspnea, musculoskeletal pain, sepsis, anemia, febrile neutropenia, hypercalcemia, nausea, pyrexia, and vomiting.

Fatalities due to adverse reactions occurred in 4.0% of patients including ILD/pneumonitis (3 patients); sepsis (2 patients); and ischemic colitis, disseminated intravascular coagulation, dyspnea, febrile neutropenia, general physical health deterioration, pleural effusion, and respiratory failure (1 patient each). ENHERTU was permanently discontinued in 16% of patients, of which ILD/pneumonitis accounted for 8%.

Dose interruptions due to adverse reactions occurred in 39% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, fatigue, anemia, leukopenia, COVID-19, ILD/pneumonitis, increased transaminases, and hyperbilirubinemia. Dose reductions occurred in 23% of patients treated with ENHERTU.

The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, thrombocytopenia, and neutropenia. The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, alopecia, vomiting, increased aspartate aminotransferase, increased alanine aminotransferase, constipation, increased blood alkaline phosphatase, decreased appetite, musculoskeletal pain, diarrhea, and decreased blood potassium.

Tables 18 and 19 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast04. Table 18: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients Treated with ENHERTU in DESTINY-Breast04 Adverse Reactions ENHERTU 5.4 mg/kg Chemotherapy N=371 N=172 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Events were graded using NCI CTCAE version 5.0.

Gastrointestinal Disorders Nausea 76 4.6 30 0 Vomiting 40 1.6 13 0 Constipation 34 0.8 22 0 Diarrhea 27 1.3 22 1.7 Abdominal pain Including abdominal pain, abdominal discomfort, lower abdominal pain, and upper abdominal pain 18 0.5 13 0 Stomatitis Including stomatitis, aphthous ulcer, mouth ulceration, and pharyngeal inflammation 13 0.3 12 0.6 General Disorders and Administration Site Conditions Fatigue Including fatigue, asthenia, and malaise 54 9 48 4.7 Pyrexia 12 0.3 13 0 Skin and Subcutaneous Tissue Disorders Alopecia 40 0 33 0 Rash Including rash, pustular rash, pruritic rash, maculo-papular rash, palmar-plantar erythrodysesthesia syndrome, papular rash, macular rash, eczema, erythema multiforme, dermatitis, urticarial dermatitis, drug eruption, and dermatitis bullous 13 0 23 4.7 Metabolism and Nutrition Disorders Decreased appetite 32 2.4 19 1.2 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including back pain, myalgia, pain in extremity, musculoskeletal pain, bone pain, musculoskeletal chest pain, arthralgia, noncardiac chest pain, musculoskeletal stiffness, arthritis, spinal pain, and neck pain 32 1.3 31 0.6 Investigations Decreased weight 16 0.3 8 0 Vascular Disorders Hemorrhage Including esophageal varices, hemorrhage, hemorrhoidal hemorrhage, epistaxis, hematuria, conjunctival hemorrhage, vaginal hemorrhage, gingival bleeding, genital hemorrhage, eye hemorrhage, hemoptysis, hemorrhagic cystitis, pharyngeal hemorrhage, rectal hemorrhage, upper gastrointestinal hemorrhage, and esophageal hemorrhage 16 0 3.5 0 Nervous System Disorders Headache Including headache and migraine 15 0.3 6 0 Peripheral neuropathy Including peripheral neuropathy, peripheral sensory neuropathy, peripheral motor neuropathy, polyneuropathy, paresthesia, hypoesthesia, dysesthesia, and neuralgia 13 0 29 5 Dizziness Including dizziness, postural dizziness, and vertigo 11 0.5 6 0 Infections and Infestations Upper respiratory tract infection Including upper respiratory tract infection, influenza, influenza-like illness, nasopharyngitis, pharyngitis, sinusitis, and rhinitis 14 0.3 5 0 Respiratory, Thoracic and Mediastinal Disorders Interstitial lung disease Interstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU: interstitial lung disease, pneumonitis, organizing pneumonia, pneumonia, and radiation pneumonitis. 12 1.3 0.6 0 Dyspnea 10 1.3 9 1.2 Other clinically relevant adverse reactions reported in less than 10% of patients treated with ENHERTU: Nervous System Disorders: dysgeusia (10%) Respiratory, Thoracic and Mediastinal Disorders: cough (10%) Gastrointestinal Disorders: abdominal distension (5%), gastritis (2.7%), flatulence (2.4%) Eye Disorders: blurred vision (4.9%) [including blurred vision and visual impairment] Skin and Subcutaneous Tissue Disorders: pruritus (3.2%) and skin hyperpigmentation (2.7%) [including skin hyperpigmentation, skin discoloration, and pigmentation disorder] Metabolism and Nutrition Disorders: dehydration (1.9%) Blood and Lymphatic System Disorders: febrile neutropenia (1.1%) Injury, Poisoning, and Procedural Complications: infusion-related reactions (0.5%) [including injection-site reaction and chills] Table 19: Selected Laboratory Abnormalities in Patients in DESTINY-Breast04 Laboratory Parameter ENHERTU 5.4 mg/kg Chemotherapy N=371 N=172 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.

Hematology Decreased white blood cell count 70 9 78 25 Decreased hemoglobin 64 8 53 6 Decreased neutrophil count 64 14 73 38 Decreased lymphocyte count 55 18 40 11 Decreased platelet count 44 6 21 0.6 Chemistry Increased aspartate aminotransferase 38 2.2 38 4.1 Increased alanine aminotransferase 36 0.8 38 4.1 Increased blood alkaline phosphatase 34 0.3 24 0 Decreased blood potassium 25 3.3 17 1.2 Increased blood bilirubin 16 2.7 15 0.6 Increased blood creatinine 15 1.1 9 0.6 HER2-Mutant Unresectable or Metastatic NSCLC DESTINY-Lung02 evaluated two dose levels (5.4 mg/kg [n=101] and 6.4 mg/kg [n=50]); however, only the results for the recommended dose of 5.4 mg/kg intravenously every 3 weeks are described below due to increased toxicity observed with the higher dose in patients with NSCLC, including ILD/pneumonitis. The safety of ENHERTU was evaluated in 101 patients in DESTINY-Lung02 [see Clinical Studies (14.4)].

Patients received ENHERTU 5.4 mg/kg intravenously once every three weeks until disease progression or unacceptable toxicity. The median duration of treatment was 8 months (range: 0.7 to 28) for patients who received ENHERTU. The median age was 59 years (range 31 to 84); 64% were female; 23% were White, 64% were Asian, and 14% were other races.

Serious adverse reactions occurred in 40% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, pleural effusion, thrombocytopenia, dyspnea, nausea, pneumonia, vomiting, myocarditis, pulmonary embolism, and increased troponin I. Fatalities due to adverse reactions occurred in 3% of patients including ILD/pneumonitis, cerebrovascular accident, and pneumococcal sepsis (one patient each).

ENHERTU was permanently discontinued due to an adverse reaction in 17% of patients. Adverse reactions which resulted in permanent discontinuation of ENHERTU were ILD/pneumonitis, pneumonia, blood bilirubin increased, hypokalemia, metastases to meninges, and myocarditis. Dose interruptions of ENHERTU due to adverse reactions occurred in 50% of patients.

Adverse reactions which required dose interruption (>2%) included neutropenia, COVID-19, ILD/pneumonitis, fatigue, anemia, and pneumonia. Dose reductions due to an adverse reaction occurred in 20% of patients. The most frequent adverse reactions (>2%) associated with dose reduction were neutropenia, fatigue, and decreased appetite.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin, nausea, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, increased aspartate aminotransferase, decreased albumin, decreased platelet count, fatigue, increased alanine aminotransferase, decreased appetite, constipation, increased alkaline phosphatase, vomiting, decreased blood potassium, diarrhea, alopecia, and musculoskeletal pain. Tables 20 and 21 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Lung02.

Table 20: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients with Unresectable or Metastatic HER2-Mutant NSCLC in DESTINY-Lung02 Adverse Reactions ENHERTU 5.4 mg/kg N=101 All Grades % Grades 3 or 4 % Events were graded using NCI CTCAE version 5.0. Gastrointestinal Disorders Nausea 67 4 Constipation 38 1 Vomiting Including vomiting and retching 32 3 Diarrhea 24 1 Stomatitis Including mucosal inflammation, stomatitis, and mouth ulceration 17 0 Abdominal pain Including abdominal discomfort, abdominal pain, and upper abdominal pain 10 0 General Disorders and Administration Site Conditions Fatigue Including asthenia, fatigue, and malaise 48 8 Metabolism and Nutrition Disorders Decreased appetite 41 2 Skin and Subcutaneous Tissue Disorders Alopecia 22 0 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including back pain, bone pain, musculoskeletal stiffness, musculoskeletal chest pain, arthralgia, musculoskeletal pain, myalgia, and pain in extremity 21 1 Respiratory, Thoracic, and Mediastinal Disorders Interstitial lung disease Interstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU including pneumonitis, interstitial lung disease, pulmonary toxicity, and respiratory failure 15 1 Infections and Infestations Upper respiratory tract infection Including influenza, influenza-like illness, upper respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, rhinitis, and laryngitis 12 0 Other clinically relevant adverse reactions reported in less than 10% of patients were: Respiratory, Thoracic, and Mediastinal Disorders: dyspnea (7%), and epistaxis (5%) Nervous System Disorders: headache (7%) [including headache and migraine] Skin and Subcutaneous Disorders: rash (6%) [including rash and rash maculo-papular] Table 21: Select Laboratory Abnormalities in Patients with Unresectable or Metastatic HER2-Mutant NSCLC in DESTINY-Lung02 Laboratory Parameter ENHERTU 5.4 mg/kg N=101 Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.

All Grades Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities. % Grades 3 or 4 % Hematology The denominator used to calculate the rate varied from 100 to 101 based on the number of patients with a baseline value and at least one post-treatment value. Decreased hemoglobin 68 12 Decreased white blood cell count 66 7 Decreased neutrophil count 59 19 Decreased lymphocyte count 56 26 Decreased platelet count 49 5 Chemistry Increased aspartate aminotransferase 51 1 Decreased albumin 50 0 Increased alanine aminotransferase 41 2 Increased alkaline phosphatase 37 0 Decreased blood potassium 29 5 HER2-Positive Locally Advanced or Metastatic Gastric Cancer The safety of ENHERTU was evaluated in 187 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma in DESTINY-Gastric01 [see Clinical Studies (14.5)].

Patients intravenously received at least one dose of either ENHERTU (N=125) 6.4 mg/kg once every three weeks or either irinotecan (N=55) 150 mg/m 2 biweekly or paclitaxel (N=7) 80 mg/m 2 weekly for 3 weeks. The median duration of treatment was 4.6 months (range: 0.7 to 22.3) in the ENHERTU group and 2.8 months (range: 0.5 to 13.1) in the irinotecan/paclitaxel group.

Serious adverse reactions occurred in 44% of patients receiving ENHERTU 6.4 mg/kg. Serious adverse reactions in >2% of patients who received ENHERTU were decreased appetite, ILD, anemia, dehydration, pneumonia, cholestatic jaundice, pyrexia, and tumor hemorrhage. Fatalities due to adverse reactions occurred in 2.4% of patients: disseminated intravascular coagulation, large intestine perforation, and pneumonia occurred in one patient each (0.8%).

ENHERTU was permanently discontinued in 15% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 62% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, decreased appetite, leukopenia, fatigue, thrombocytopenia, ILD, pneumonia, lymphopenia, upper respiratory tract infection, diarrhea, and decreased blood potassium.

Dose reductions occurred in 32% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were neutropenia, decreased appetite, fatigue, nausea, and febrile neutropenia. The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, nausea, decreased appetite, increased aspartate aminotransferase, fatigue, increased blood alkaline phosphatase, increased alanine aminotransferase, diarrhea, decreased blood potassium, vomiting, constipation, increased blood bilirubin, pyrexia, and alopecia.

Tables 22 and 23 summarize adverse reactions and laboratory abnormalities observed in patients receiving ENHERTU 6.4 mg/kg in DESTINY-Gastric01. Table 22: Adverse Reactions in ≥10% All Grades or ≥2% Grades 3 or 4 of Patients Receiving ENHERTU in DESTINY-Gastric01 ENHERTU 6.4 mg/kg N=125 Irinotecan or Paclitaxel N=62 Adverse Reactions All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Events were graded using NCI CTCAE version 4.03.

Gastrointestinal Disorders Nausea 63 4.8 47 1.6 Diarrhea 32 2.4 32 1.6 Vomiting 26 0 8 0 Constipation 24 0 23 0 Abdominal pain Including abdominal discomfort, gastrointestinal pain, abdominal pain, lower abdominal pain, and upper abdominal pain 14 0.8 15 3.2 Stomatitis Including stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosal blistering 11 1.6 4.8 0 Metabolism and Nutrition Disorders Decreased appetite 60 17 45 13 Dehydration 6 2.4 3.2 1.6 Blood and Lymphatic System Disorders Febrile neutropenia 4.8 4.8 3.2 3.2 General Disorders and Administration Site Conditions Fatigue Including fatigue, asthenia, and malaise 55 9 44 4.8 Pyrexia 24 0 16 0 Peripheral edema 10 0 0 0 Skin and Subcutaneous Tissue Disorders Alopecia 22 0 15 0 Respiratory, Thoracic and Mediastinal Disorders Interstitial lung disease Interstitial lung disease includes events that were adjudicated as drug-induced ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, and alveolitis. 10 2.4 0 0 Hepatobiliary Disorders Abnormal hepatic function 8 3.2 1.6 1.6 Other clinically relevant adverse reactions reported in less than 10% of patients were: Cardiac Disorders: asymptomatic left ventricular ejection fraction decrease (8%) [see Warnings and Precautions (5.3)] Infections and Infestations: pneumonia (6%) Injury, Poisoning, and Procedural Complications: infusion-related reactions (1.6%) Table 23: Selected Laboratory Abnormalities Occurring in Patients Receiving ENHERTU in DESTINY-Gastric01 Laboratory Parameter ENHERTU 6.4 mg/kg N=125 Irinotecan or Paclitaxel N=62 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.4.03 grade-derived laboratory abnormalities.

Hematology Decreased hemoglobin 75 38 55 23 Decreased white blood cell count 74 29 53 13 Decreased neutrophil count 72 51 45 23 Decreased lymphocyte count 70 28 53 12 Decreased platelet count 68 12 12 5 Chemistry Increased aspartate aminotransferase 58 9 32 8 Increased blood alkaline phosphatase 54 8 34 10 Increased alanine aminotransferase 47 9 17 1.7 Decreased blood potassium 30 4.8 18 8 Increased blood bilirubin 24 7 5 3.4 HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors The safety of ENHERTU was evaluated in 347 adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received ENHERTU 5.4 mg/kg in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 [see Clinical Studies (14.2 and 14.6)]. ENHERTU was administered by intravenous infusion once every three weeks.

The median duration of treatment was 8.3 months (range 0.7 to 30.2). The median age was 60 years (range 23 to 96); 74% were female; 51% were White, 42% were Asian, 2.9% were Black or African American, 3.5% were of Hispanic or Latino ethnicity; and 51% had an ECOG performance status 0 and 48% had an ECOG performance status of 1.

Serious adverse reactions occurred in 34% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were sepsis, pneumonia, vomiting, urinary tract infection, abdominal pain, nausea, pneumonitis, pleural effusion, hemorrhage, COVID-19, fatigue, acute kidney injury, anemia, cellulitis, and dyspnea.

Fatalities due to adverse reactions occurred in 6.3% of patients including ILD/pneumonitis (2.3%), cardiac arrest (0.6%), COVID-19 (0.6%), and sepsis (0.6%). The following events occurred in one patient each (0.3%): acute kidney injury, cerebrovascular accident, general physical health deterioration, pneumonia, and hemorrhagic shock.

ENHERTU was permanently discontinued in 15% of patients, of which ILD/pneumonitis accounted for 10%. Dose interruptions due to adverse reactions occurred in 48% of patients. The most frequent adverse reactions (>2%) associated with dose interruption were decreased neutrophil count, anemia, COVID-19, fatigue, decreased white blood cell count, and ILD/pneumonitis.

Dose reductions occurred in 27% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, decreased neutrophil count, ILD/pneumonitis, and diarrhea. The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count, nausea, decreased hemoglobin, decreased neutrophil count, fatigue, decreased lymphocyte count, decreased platelet count, increased aspartate aminotransferase, increased alanine aminotransferase, increased blood alkaline phosphatase, vomiting, decreased appetite, alopecia, diarrhea, decreased blood potassium, constipation, decreased sodium, stomatitis, and upper respiratory tract infection.

Tables 24 and 25 summarize the common adverse reactions and laboratory abnormalities in DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-Breast01, and DESTINY-CRC02. Table 24: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in HER2-positive (IHC 3+) Patients Treated with ENHERTU in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 Adverse Reactions ENHERTU 5.4 mg/kg N= 347 All Grades % Grade 3 or 4 % Gastrointestinal Disorders Nausea 69 7 Vomiting 35 3.5 Diarrhea 31 4.3 Constipation 28 0.6 Stomatitis Including stomatitis, mucosal inflammation, aphthous ulcer, mouth ulceration, oral mucosa erosion, oral mucosal blistering, oral mucosal eruption, tongue ulceration, cheilitis. 20 0.9 Abdominal pain Including abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, gastrointestinal pain. 18 2 Dyspepsia 12 0.3 General Disorders and Administration Site Conditions Fatigue Including fatigue, asthenia, malaise, lethargy. 59 10 Pyrexia 11 0 Edema Including peripheral edema, edema, localized edema, face edema, skin edema, periorbital edema, eyelid edema 11 0.6 Metabolism and Nutrition Disorders Decreased appetite 34 2.6 Skin and Subcutaneous Tissue Disorders Alopecia 34 0.3 Rash Including rash, pustular rash, maculo-papular rash, papular rash, macular rash, pruritic rash dermatitis acneiform, dermatitis, eczema, palmar-plantar erythrodysesthesia syndrome. 13 0.6 Infections and Infestations Upper respiratory tract infection Including influenza, influenza-like illness, upper respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, rhinitis, laryngitis. 20 0 Pneumonia 6 2.3 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Including back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain, limb discomfort. 19 0.3 Respiratory, Thoracic and Mediastinal Disorders Cough Including cough, productive cough, upper-airway cough syndrome 18 0 Interstitial lung disease Interstitial lung disease includes events that were adjudicated as drug-induced ILD: pneumonitis, ILD, organizing pneumonia, respiratory failure, acute respiratory failure, alveolitis, lung opacity, lymphangitis, pneumonia, bacterial pneumonia, pulmonary fibrosis, and radiation pneumonitis.

Grade 5 adjudicated drug-induced ILD events were pneumonitis, respiratory failure, acute respiratory failure, lymphangitis, pulmonary fibrosis. 16 0.6 Dyspnea Including dyspnea, exertional dyspnea 12 1.7 Nervous System Disorders Headache Including migraine, headache, sinus headache. 15 0 Investigations Decreased weight 10 0.3 Other clinically relevant adverse reactions reported in less than 10% of patients were: Respiratory, Thoracic, and Mediastinal Disorders: epistaxis (9%) Nervous System Disorders: dizziness (9%) [including dizziness, postural dizziness, and vertigo] and dysgeusia (6%) Skin and Subcutaneous Disorders: pruritus (5%) and skin hyperpigmentation (4.3%) [including skin hyperpigmentation, skin discoloration, pigmentation disorder] Eye Disorders: blurred vision (4%) [including blurred vision, visual impairment] Metabolism and Nutrition Disorders: dehydration (3.2%) Gastrointestinal Disorders: abdominal distension (2.6%), flatulence (1.7%) and gastritis (0.9%) Blood and Lymphatic System Disorders: febrile neutropenia (1.7%) Injury, Poisoning, and Procedural Complications: infusion-related reactions (1.4%) [including administration related reaction, anaphylactic reaction, hypersensitivity, infusion-related reaction and infusion-related hypersensitivity reaction] Table 25: Selected Laboratory Abnormalities in HER2-positive (IHC 3+) Patients Treated with ENHERTU in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 Laboratory Parameter ENHERTU 5.4 mg/kg N= 347 Percentages were calculated using the number of patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. All Grades % Grades 3 or 4 % Hematology Decreased white blood cell count 75 11 Decreased hemoglobin 67 10 Decreased neutrophil count 66 21 Decreased lymphocyte count 58 21 Decreased platelet count 51 7 Chemistry Increased aspartate aminotransferase 45 1.5 Increased alanine aminotransferase 44 1.5 Increased blood alkaline phosphatase 36 1.2 Decreased blood potassium 29 6 Decreased sodium 22 2.9 Increased blood bilirubin 15 0.6 Increased blood creatinine 14 0.6

Adverse reaction frequency tables (US label) US FDA label
Table 4: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) Patients in DESTINY-Breast11
Adverse ReactionsENHERTU 5.4 mg/kg followed by THP N = 320ddAC followed by THP N = 312
All Grades %Grade 3 or 4 %All Grades %Grade 3 or 4 %
THP= paclitaxel, trastuzumab, and pertuzumab; ddAC=dose dense doxorubicin and cyclophosphamide; Events were graded using NCI CTCAE version 5.0.
Gastrointestinal Disorders
Nausea651.9520.3
Diarrhea596543.2
Constipation290.3240
Vomiting290.9210.6
Stomatitis Including aphthous ulcer, cheilitis, glossitis, mouth ulceration, mucosal inflammation, and stomatitis.230.3361.0
Abdominal painIncluding abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and gastrointestinal pain.160120
Nervous System Disorders
Peripheral neuropathyIncluding dysesthesia, hypoesthesia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.592.5472.2
HeadacheIncluding headache, migraine, and sinus headache. 180160
Skin and Subcutaneous Tissue Disorders
Alopecia480490
RashIncluding dermatitis, dermatitis acneiform, dermatitis bullous, eczema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, skin exfoliation, and urticarial dermatitis.310.9251.0
General Disorders and Administration Site Conditions
FatigueIncluding asthenia, fatigue, and malaise.410.6552.2
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding arthralgia, back pain, bone pain, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and pain in extremity.300280.3
Metabolism and Nutrition Disorders
Decreased appetite200180.3
Respiratory, Thoracic and Mediastinal Disorders
Epistaxis150100
Cough100140
Infections and Infestations
Upper respiratory tract infectionIncluding influenza, influenza-like illness, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection.130.6200.3
COVID-19100.9110.3
Table 5: Selected Laboratory Abnormalities in Patients in DESTINY-Breast11
Laboratory ParameterENHERTU 5.4 mg/kg followed by THP N=320ddAC followed by THP N = 312
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
THP= paclitaxel, trastuzumab, and pertuzumab; ddAC= dose dense doxorubicin and cyclophosphamide Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.
Hematology
Decreased hemoglobin832.29710
Decreased white blood cell count6788731
Decreased neutrophil count58176638
Decreased lymphocyte count403.19339
Decreased platelet count80.9282.9
Chemistry
Increased alanine aminotransferase795774.2
Increased aspartate aminotransferase742.5681
Decreased blood potassium294.1254.5
Increased blood alkaline phosphatase190240
Decreased sodium191.9232.6
Increased blood creatinine80.681.3
Increased blood bilirubin704.20.6
Table 6: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3-4) in Patients Treated with ENHERTU in DESTINY-Breast05
Adverse ReactionsENHERTU 5.4 mg/kg N= 806Ado-Trastuzumab Emtansine (T-DM1) 3.6mg/kg N=801
All Grades %Grade 3 or 4 %All Grades %Grades 3 or 4 %
Events were graded using NCI CTCAE version 5.0.
Gastrointestinal Disorders
Nausea714.5290.1
Constipation320160.1
Vomiting311.190.1
Diarrhea231.290.4
Abdominal pain Including abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and gastrointestinal pain.150.290.1
Stomatitis Including aphthous ulcer, cheilitis, mouth ulceration, mucosal inflammation, pharyngeal inflammation, and stomatitis.100.260.1
General Disorders and Administration Site Conditions
FatigueIncluding asthenia, fatigue, lethargy, and malaise.546371.0
Pyrexia100.1120.2
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding arthralgia, back pain, bone pain, limb discomfort, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and pain in extremity.230.7320.6
Metabolism and Nutrition Disorders
Decreased appetite200.9100
Infections and Infestations
Upper respiratory tract infectionIncluding influenza, influenza like illness, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection. 180.1170.5
COVID-19170.5200.4
Respiratory, Thoracic and Mediastinal Disorders
Interstitial lung diseaseIncluding COVID-19 pneumonia, interstitial lung disease, lung opacity, organizing pneumonia, pneumocystis jirovecii pneumonia, pneumonia, and pneumonitis which was adjudicated as ILD (irrespective of causality). Adjudicated drug-related ILD for ENHERTU was 10% for all Grades and 0.9% for Grades 3 or 4 and for T-DM1, 1.6% for all Grades and 0% for Grades 3 or 4. 171.13.70.2
Cough130110
Nervous System Disorders
HeadacheIncluding headache, migraine, and sinus headache.160.2210.1
Peripheral neuropathyIncluding dysesthesia, hyperesthesia, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.130.4201.1
DizzinessIncluding dizziness, dizziness postural, vertigo, and vertigo positional.110.470.1
Skin and Subcutaneous Tissue Disorders
Alopecia1601.20
RashIncluding dermatitis, dermatitis acneiform, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema, eczema asteatotic, erythema multiforme, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, skin exfoliation, and Stevens-Johnson syndrome.100.4140.1
Investigations
Decreased weight120.270.1
Table 7: Selected Laboratory Abnormalities in Patients in DESTINY-Breast05
Laboratory ParameterENHERTU 5.4 mg/kg N=806Ado-Trastuzumab Emtansine (T-DM1) 3.6mg/kg N = 801
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.
Hematology
Decreased white blood cell count8017462.3
Decreased lymphocyte count72355417
Decreased neutrophil count7223384.9
Decreased hemoglobin612.9362
Decreased platelet count4689333
Chemistry
Increased aspartate aminotransferase601914.3
Increased alanine aminotransferase531804.2
Increased blood alkaline phosphatase390530.1
Decreased blood potassium271.7442.1
Increased blood creatinine130.290.1
Increased blood bilirubin90200
Table 8: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients Treated with ENHERTU in Combination with Pertuzumab in DESTINY-Breast09
Adverse ReactionsENHERTU 5.4 mg/kg + Pertuzumab N= 381THPTHP=taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab N=382
All Grades %Grade 3-4 %All Grades %Grades 3-4 %
Gastrointestinal Disorders
Nausea755340.3
Diarrhea648626
Vomiting462.4180.5
Constipation330.3120
Abdominal painIncluding abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and gastrointestinal pain. 230.3130
StomatitisIncluding aphthous ulcer, mouth ulceration, oral mucosal eruption, and stomatitis. 161.3171.3
Dyspepsia12060
General Disorders and Administration Site Conditions
FatigueIncluding asthenia, fatigue, lethargy, and malaise. 538422.1
Pyrexia160181.0
Skin and Subcutaneous Tissue Disorders
Alopecia480530.5
RashIncluding rash, rash macular, rash maculo-papular, rash pruritic, and rash pustular.170.3220.3
Pruritus110110.3
Infections and Infestations
Upper respiratory tract infectionIncluding Influenza, Influenza like illness, laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection.331.6300.5
COVID-19280.3220.3
Metabolism and Nutrition Disorders
Decreased appetite322.4180.8
Hypoalbuminemia110.380.3
Investigations
Decreased weight303.1110.8
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding back pain, bone pain, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, and pain in extremity. 241330.3
Nervous System Disorders
HeadacheIncluding headache and migraine. 190.3140
Dysgeusia13090
Dizziness120.3100
Respiratory, Thoracic, and Mediastinal Disorders
Cough170.3130
Interstitial lung diseaseInterstitial lung disease includes chronic obstructive pulmonary disease (n=1), interstitial lung disease (n=23), pneumonia (n=3), and pneumonitis (n=22). These events were adjudicated as ILD and related to use of ENHERTU12010
Eye Disorders
Dry eye11060
Table 9: Selected Laboratory Abnormalities in Patients in DESTINY-Breast09
Laboratory ParameterENHERTU 5.4 mg/kg + Pertuzumab N= 381THPTHP=taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab] N=382
All Grades %Grade 3-4 %All Grades %Grades 3-4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.
Hematology
Decreased white blood cell count87118231
Decreased hemoglobin8012866
Decreased neutrophil count78296640
Decreased lymphocyte count62145811
Decreased platelet count568201.9
Chemistry
Increased alanine aminotransferase663.2451.9
Increased aspartate aminotransferase622.1411.9
Increased blood alkaline phosphatase550.3360.3
Decreased blood potassium5420296
Increased blood bilirubin230.3100.3
Increased blood creatinine91.870.3
Table 10: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3-4) in Patients Treated with ENHERTU in DESTINY-Breast03
Adverse ReactionsENHERTU 5.4 mg/kg N=257Ado-trastuzumab emtansine 3.6 mg/kg N=261
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
Events were graded using NCI CTCAE version 5.0.
Gastrointestinal Disorders
Nausea767300.4
Vomiting491.6100.8
Constipation340200
Diarrhea291.270.4
Abdominal painIncluding abdominal pain, abdominal discomfort, lower abdominal pain, and upper abdominal pain.210.880.4
Stomatitis Including stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosal eruption. 200.850
Dyspepsia11060
General Disorders and Administration Site Conditions
FatigueIncluding fatigue, asthenia, malaise, and lethargy.496350.8
Skin and Subcutaneous Tissue Disorders
AlopeciaThis Grade 3 event was reported by the investigator. Per NCI CTCAE v.5.0, the highest NCI CTCAE grade for alopecia is Grade 2.370.43.10
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain, and limb discomfort.311.2250.4
Metabolism and Nutrition Disorders
Decreased appetite291.6170.4
Investigations
Decreased weight171.260.4
Respiratory, Thoracic, and Mediastinal Disorders
Respiratory infectionIncluding respiratory tract infection, lower and upper respiratory tract infection, pneumonia, influenza, influenza-like illness, viral upper respiratory infection, bronchitis, and respiratory syncytial virus infection.220.8121.1
Epistaxis110160.4
Cough110.4100
Interstitial lung diseaseInterstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU: pneumonitis, interstitial lung disease, organizing pneumonia, pneumonia, and pulmonary mass. For ado-trastuzumab emtansine: pneumonitis, interstitial lung disease, organizing pneumonia, and pulmonary embolism.110.81.90
Nervous System Disorders
HeadacheIncluding headache and migraine.220.4160
Peripheral neuropathyIncluding peripheral neuropathy, peripheral sensory neuropathy, and paresthesia.130.4140.4
Dizziness130.480
Table 11: Selected Laboratory Abnormalities in Patients in DESTINY-Breast03
Laboratory ParameterENHERTU 5.4 mg/kg N=257Ado-trastuzumab emtansine 3.6 mg/kg N=261
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.
Hematology
Decreased white blood cell count748240.8
Decreased neutrophil count7018302.3
Decreased hemoglobin647386
Decreased lymphocyte count5514233.9
Decreased platelet count5277924
Chemistry
Increased aspartate aminotransferase670.8835
Increased alanine aminotransferase531.6676
Increased blood alkaline phosphatase490.8460.8
Decreased blood potassium354.7391.5
Increased blood bilirubin200140
Increased blood creatinine160.880.4
Table 12: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3-4) in Patients Treated with ENHERTU in DESTINY-Breast02
Adverse ReactionsENHERTU 5.4 mg/kg N=404Treatment of Physician's Choice N=195
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
Events were graded using NCI CTCAE version 5.0.
Gastrointestinal Disorders
Nausea737372.6
Vomiting383.7131
Constipation350.3110.5
Diarrhea272.7547
Abdominal painIncluding abdominal discomfort, abdominal pain, upper abdominal pain, lower abdominal pain, and gastrointestinal pain221202.1
Dyspepsia12090
StomatitisIncluding aphthous ulcer, mouth ulceration, and stomatitis 121211
General Disorders and Administration Site Conditions
FatigueIncluding asthenia, fatigue, lethargy, and malaise629371
Skin and Subcutaneous Tissue Disorders
Alopecia370.34.10
Metabolism and Nutrition Disorders
Decreased appetite311.7180.5
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding back pain, bone pain, limb discomfort, musculoskeletal chest pain, musculoskeletal pain, muscle spasms, myalgia, neck pain, and pain in extremity 250.7180.5
Nervous System Disorders
HeadacheIncluding headache and migraine200.360
Investigations
Decreased weight180.33.60
Respiratory, Thoracic, and Mediastinal Disorders
Cough130100
Interstitial lung diseaseInterstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU: pneumonitis, interstitial lung disease, idiopathic interstitial pneumonia, lung disorder, pulmonary toxicity, and pneumonia.100.70.50.5
Table 13: Selected Laboratory Abnormalities in Patients in DESTINY-Breast02
Laboratory ParameterENHERTU 5.4 mg/kg N=404Treatment of Physician's Choice N=195
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.
Hematology
Decreased white blood cell count7012423.2
Decreased hemoglobin679543.2
Decreased neutrophil count6416344.7
Decreased lymphocyte count5817384.7
Decreased platelet count482.7311.6
Chemistry
Increased alanine aminotransferase431321.6
Increased aspartate aminotransferase370.7292.1
Increased blood alkaline phosphatase370170
Decreased blood potassium303.7298
Increased blood bilirubin230.3442.1
Increased blood creatinine70.3130
Table 14: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients in DESTINY-Breast01 and Study DS8201-A-J101
Adverse ReactionsENHERTU 5.4 mg/kg N=234
All Grades %Grades 3 or 4 %
Events were graded using NCI CTCAE version 4.03.
Gastrointestinal Disorders
Nausea797
Vomiting473.8
Constipation350.9
Diarrhea291.7
Abdominal painIncluding abdominal discomfort, gastrointestinal pain, abdominal pain, lower abdominal pain, and upper abdominal pain191.3
Stomatitis Including stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosa blistering. One Grade 1 event of aphthous ulcer was not included in the summary of grouped term stomatitis (from DESTINY-Breast01).140.9
Dyspepsia120
General Disorders and Administration Site Conditions
FatigueIncluding fatigue and asthenia596
Skin and Subcutaneous Tissue Disorders
Alopecia460.4This Grade 3 event was reported by the investigator. Per NCI CTCAE v.4.03, the highest NCI CTCAE grade for alopecia is Grade 2.
RashIncluding rash, pustular rash, and maculo-papular rash100
Metabolism and Nutrition Disorders
Decreased appetite321.3
Respiratory, Thoracic, and Mediastinal Disorders
Cough200
Dyspnea131.3
Epistaxis130
Interstitial lung diseaseInterstitial lung disease includes events that were adjudicated as drug-induced ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, and alveolitis.92.6All events had fatal outcomes (n=6).
Nervous System Disorders
HeadacheIncluding headache, sinus headache, and migraine190
Dizziness100
Infections and Infestations
Upper respiratory tract infectionIncluding influenza, influenza-like illness, and upper respiratory tract infection150
Eye Disorders
Dry eye110.4This Grade 4 event was reported by the investigator. Per NCI CTCAE v.4.03, the highest NCI CTCAE grade for dry eye is Grade 3.
Table 15: Selected Laboratory Abnormalities in Patients with Unresectable or Metastatic HER2-positive Breast Cancer Treated with ENHERTU in DESTINY-Breast01 and Study DS8201-A-J101
Laboratory ParameterENHERTU 5.4 mg/kg N=234
All Grades %Grades 3 or 4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.
Frequencies were based on NCI CTCAE v.4.03 grade-derived laboratory abnormalities.
Hematology
Decreased white blood cell count707
Decreased hemoglobin707
Decreased neutrophil count6216
Decreased platelet count373.4
Chemistry
Increased aspartate aminotransferase410.9
Increased alanine aminotransferase380.4
Decreased blood potassium263
Table 16: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients Treated with ENHERTU in DESTINY-Breast06
Adverse ReactionsENHERTU 5.4 mg/kgChemotherapy
N=434N=417
All Grades %Grades 3 or 4 %All Grades %Grades 3 or 4 %
Events were graded using NCI CTCAE version 5.0.
Gastrointestinal Disorders
Nausea702.1300.5
Diarrhea342.3272.6
Vomiting341.4120.2
Constipation320.7150.5
Abdominal painIncluding abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and gastrointestinal pain.200.5140.2
StomatitisIncluding stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, oral mucosal blistering, and oral mucosal eruption.150110.5
Dyspepsia1204.80
General Disorders and Administration Site Conditions
FatigueIncluding fatigue, asthenia, malaise, and lethargy.534.4402.4
Pyrexia120.270
Skin and Subcutaneous Tissue Disorders
Alopecia480210.5
RashIncluding dermatitis, dermatitis allergic, dermatitis contact, eczema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, and rash pustular.120.2438
Metabolism and Nutrition Disorders
Decreased appetite261.4120.5
Infections and Infestations
COVID-19Including COVID-19, COVID-19 pneumonia. 260.9131
Upper respiratory tract infectionIncluding influenza, influenza-like illness, upper respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, rhinitis, and laryngitis.19090
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain, and limb discomfort.240.5231.9
Nervous System Disorders
HeadacheIncluding migraine, headache, and sinus headache.180.5100
Dysgeusia120.260
Respiratory, Thoracic, and Mediastinal Disorders
Cough16090
Interstitial lung diseaseIncluding bronchiectasis, interstitial lung disease, lower respiratory tract infection, pneumonia, pneumonia bacterial, pneumonitis, and pulmonary toxicity. 110.70.20
Epistaxis1003.60.2
Table 17: Selected Laboratory Abnormalities in Patients in DESTINY-Breast06
Laboratory ParameterENHERTU 5.4 mg/kgChemotherapy
N=434N=417
All Grades %Grades 3 or 4 %All Grades %Grades 3 or 4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.
Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.
Hematology
Decreased white blood cell count86137111
Decreased neutrophil count75275320
Decreased hemoglobin699585
Decreased lymphocyte count6619468
Decreased platelet count486251
Chemistry
Increased alanine aminotransferase443.2300.7
Increased blood alkaline phosphatase430.2220.2
Increased aspartate aminotransferase412.6271.2
Decreased blood potassium358152.9
Increased blood bilirubin161.9231.5
Increased blood creatinine101.981
Table 18: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients Treated with ENHERTU in DESTINY-Breast04
Adverse ReactionsENHERTU 5.4 mg/kgChemotherapy
N=371N=172
All Grades %Grades 3 or 4 %All Grades %Grades 3 or 4 %
Events were graded using NCI CTCAE version 5.0.
Gastrointestinal Disorders
Nausea764.6300
Vomiting401.6130
Constipation340.8220
Diarrhea271.3221.7
Abdominal painIncluding abdominal pain, abdominal discomfort, lower abdominal pain, and upper abdominal pain180.5130
StomatitisIncluding stomatitis, aphthous ulcer, mouth ulceration, and pharyngeal inflammation130.3120.6
General Disorders and Administration Site Conditions
FatigueIncluding fatigue, asthenia, and malaise549484.7
Pyrexia120.3130
Skin and Subcutaneous Tissue Disorders
Alopecia400330
RashIncluding rash, pustular rash, pruritic rash, maculo-papular rash, palmar-plantar erythrodysesthesia syndrome, papular rash, macular rash, eczema, erythema multiforme, dermatitis, urticarial dermatitis, drug eruption, and dermatitis bullous130234.7
Metabolism and Nutrition Disorders
Decreased appetite322.4191.2
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding back pain, myalgia, pain in extremity, musculoskeletal pain, bone pain, musculoskeletal chest pain, arthralgia, noncardiac chest pain, musculoskeletal stiffness, arthritis, spinal pain, and neck pain321.3310.6
Investigations
Decreased weight160.380
Vascular Disorders
HemorrhageIncluding esophageal varices, hemorrhage, hemorrhoidal hemorrhage, epistaxis, hematuria, conjunctival hemorrhage, vaginal hemorrhage, gingival bleeding, genital hemorrhage, eye hemorrhage, hemoptysis, hemorrhagic cystitis, pharyngeal hemorrhage, rectal hemorrhage, upper gastrointestinal hemorrhage, and esophageal hemorrhage1603.50
Nervous System Disorders
HeadacheIncluding headache and migraine150.360
Peripheral neuropathyIncluding peripheral neuropathy, peripheral sensory neuropathy, peripheral motor neuropathy, polyneuropathy, paresthesia, hypoesthesia, dysesthesia, and neuralgia130295
DizzinessIncluding dizziness, postural dizziness, and vertigo110.560
Infections and Infestations
Upper respiratory tract infectionIncluding upper respiratory tract infection, influenza, influenza-like illness, nasopharyngitis, pharyngitis, sinusitis, and rhinitis140.350
Respiratory, Thoracic and Mediastinal Disorders
Interstitial lung diseaseInterstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU: interstitial lung disease, pneumonitis, organizing pneumonia, pneumonia, and radiation pneumonitis.121.30.60
Dyspnea101.391.2
Table 19: Selected Laboratory Abnormalities in Patients in DESTINY-Breast04
Laboratory ParameterENHERTU 5.4 mg/kgChemotherapy
N=371N=172
All Grades %Grades 3 or 4 %All Grades %Grades 3 or 4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.
Hematology
Decreased white blood cell count7097825
Decreased hemoglobin648536
Decreased neutrophil count64147338
Decreased lymphocyte count55184011
Decreased platelet count446210.6
Chemistry
Increased aspartate aminotransferase382.2384.1
Increased alanine aminotransferase360.8384.1
Increased blood alkaline phosphatase340.3240
Decreased blood potassium253.3171.2
Increased blood bilirubin162.7150.6
Increased blood creatinine151.190.6
Table 20: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients with Unresectable or Metastatic HER2-Mutant NSCLC in DESTINY-Lung02
Adverse ReactionsENHERTU 5.4 mg/kg N=101
All Grades %Grades 3 or 4 %
Events were graded using NCI CTCAE version 5.0.
Gastrointestinal Disorders
Nausea674
Constipation381
VomitingIncluding vomiting and retching323
Diarrhea241
StomatitisIncluding mucosal inflammation, stomatitis, and mouth ulceration170
Abdominal painIncluding abdominal discomfort, abdominal pain, and upper abdominal pain100
General Disorders and Administration Site Conditions
FatigueIncluding asthenia, fatigue, and malaise488
Metabolism and Nutrition Disorders
Decreased appetite412
Skin and Subcutaneous Tissue Disorders
Alopecia220
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding back pain, bone pain, musculoskeletal stiffness, musculoskeletal chest pain, arthralgia, musculoskeletal pain, myalgia, and pain in extremity211
Respiratory, Thoracic, and Mediastinal Disorders
Interstitial lung diseaseInterstitial lung disease includes events that were adjudicated as drug-induced ILD for ENHERTU including pneumonitis, interstitial lung disease, pulmonary toxicity, and respiratory failure 151
Infections and Infestations
Upper respiratory tract infectionIncluding influenza, influenza-like illness, upper respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, rhinitis, and laryngitis120
Table 21: Select Laboratory Abnormalities in Patients with Unresectable or Metastatic HER2-Mutant NSCLC in DESTINY-Lung02
Laboratory ParameterENHERTU 5.4 mg/kg N=101Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.
All GradesFrequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities. %Grades 3 or 4 %
HematologyThe denominator used to calculate the rate varied from 100 to 101 based on the number of patients with a baseline value and at least one post-treatment value.
Decreased hemoglobin6812
Decreased white blood cell count667
Decreased neutrophil count5919
Decreased lymphocyte count5626
Decreased platelet count495
Chemistry
Increased aspartate aminotransferase511
Decreased albumin500
Increased alanine aminotransferase412
Increased alkaline phosphatase370
Decreased blood potassium295
Table 22: Adverse Reactions in ≥10% All Grades or ≥2% Grades 3 or 4 of Patients Receiving ENHERTU in DESTINY-Gastric01
ENHERTU 6.4 mg/kg N=125Irinotecan or Paclitaxel N=62
Adverse ReactionsAll Grades %Grades 3 or 4 %All Grades %Grades 3 or 4 %
Events were graded using NCI CTCAE version 4.03.
Gastrointestinal Disorders
Nausea634.8471.6
Diarrhea322.4321.6
Vomiting26080
Constipation240230
Abdominal painIncluding abdominal discomfort, gastrointestinal pain, abdominal pain, lower abdominal pain, and upper abdominal pain140.8153.2
StomatitisIncluding stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosal blistering111.64.80
Metabolism and Nutrition Disorders
Decreased appetite60174513
Dehydration62.43.21.6
Blood and Lymphatic System Disorders
Febrile neutropenia4.84.83.23.2
General Disorders and Administration Site Conditions
FatigueIncluding fatigue, asthenia, and malaise559444.8
Pyrexia240160
Peripheral edema10000
Skin and Subcutaneous Tissue Disorders
Alopecia220150
Respiratory, Thoracic and Mediastinal Disorders
Interstitial lung diseaseInterstitial lung disease includes events that were adjudicated as drug-induced ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, and alveolitis.102.400
Hepatobiliary Disorders
Abnormal hepatic function83.21.61.6
Table 23: Selected Laboratory Abnormalities Occurring in Patients Receiving ENHERTU in DESTINY-Gastric01
Laboratory ParameterENHERTU 6.4 mg/kg N=125Irinotecan or Paclitaxel N=62
All Grades %Grades 3 or 4 %All Grades %Grades 3 or 4 %
Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator. Frequencies were based on NCI CTCAE v.4.03 grade-derived laboratory abnormalities.
Hematology
Decreased hemoglobin75385523
Decreased white blood cell count74295313
Decreased neutrophil count72514523
Decreased lymphocyte count70285312
Decreased platelet count6812125
Chemistry
Increased aspartate aminotransferase589328
Increased blood alkaline phosphatase5483410
Increased alanine aminotransferase479171.7
Decreased blood potassium304.8188
Increased blood bilirubin24753.4
Table 24: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in HER2-positive (IHC 3+) Patients Treated with ENHERTU in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02
Adverse ReactionsENHERTU 5.4 mg/kg N= 347
All Grades %Grade 3 or 4 %
Gastrointestinal Disorders
Nausea697
Vomiting353.5
Diarrhea314.3
Constipation280.6
StomatitisIncluding stomatitis, mucosal inflammation, aphthous ulcer, mouth ulceration, oral mucosa erosion, oral mucosal blistering, oral mucosal eruption, tongue ulceration, cheilitis.200.9
Abdominal painIncluding abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, gastrointestinal pain.182
Dyspepsia120.3
General Disorders and Administration Site Conditions
FatigueIncluding fatigue, asthenia, malaise, lethargy.5910
Pyrexia110
EdemaIncluding peripheral edema, edema, localized edema, face edema, skin edema, periorbital edema, eyelid edema 110.6
Metabolism and Nutrition Disorders
Decreased appetite342.6
Skin and Subcutaneous Tissue Disorders
Alopecia340.3
RashIncluding rash, pustular rash, maculo-papular rash, papular rash, macular rash, pruritic rash dermatitis acneiform, dermatitis, eczema, palmar-plantar erythrodysesthesia syndrome.130.6
Infections and Infestations
Upper respiratory tract infectionIncluding influenza, influenza-like illness, upper respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, rhinitis, laryngitis.200
Pneumonia62.3
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal painIncluding back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain, limb discomfort.190.3
Respiratory, Thoracic and Mediastinal Disorders
CoughIncluding cough, productive cough, upper-airway cough syndrome180
Interstitial lung diseaseInterstitial lung disease includes events that were adjudicated as drug-induced ILD: pneumonitis, ILD, organizing pneumonia, respiratory failure, acute respiratory failure, alveolitis, lung opacity, lymphangitis, pneumonia, bacterial pneumonia, pulmonary fibrosis, and radiation pneumonitis. Grade 5 adjudicated drug-induced ILD events were pneumonitis, respiratory failure, acute respiratory failure, lymphangitis, pulmonary fibrosis.160.6
DyspneaIncluding dyspnea, exertional dyspnea121.7
Nervous System Disorders
HeadacheIncluding migraine, headache, sinus headache.150
Investigations
Decreased weight100.3
Table 25: Selected Laboratory Abnormalities in HER2-positive (IHC 3+) Patients Treated with ENHERTU in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02
Laboratory ParameterENHERTU 5.4 mg/kg N= 347Percentages were calculated using the number of patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.
All Grades %Grades 3 or 4 %
Hematology
Decreased white blood cell count7511
Decreased hemoglobin6710
Decreased neutrophil count6621
Decreased lymphocyte count5821
Decreased platelet count517
Chemistry
Increased aspartate aminotransferase451.5
Increased alanine aminotransferase441.5
Increased blood alkaline phosphatase361.2
Decreased blood potassium296
Decreased sodium222.9
Increased blood bilirubin150.6
Increased blood creatinine140.6

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on its mechanism of action, ENHERTU can cause fetal harm when administered to a pregnant woman. There are no available data on the use of ENHERTU in pregnant women. In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death (see Data).

Based on its mechanism of action, the topoisomerase inhibitor component of ENHERTU, DXd, can also cause embryo-fetal harm when administered to a pregnant woman because it is genotoxic and targets actively dividing cells [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Advise patients of the potential risks to a fetus.

There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months after the last dose of ENHERTU (see Clinical Considerations). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Monitor women who received ENHERTU during pregnancy or within 7 months prior to conception for oligohydramnios.

If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care. Data Human Data There are no available data on the use of ENHERTU in pregnant women. In postmarketing reports in pregnant women receiving a HER2-directed antibody, cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported.

These case reports described oligohydramnios in pregnant women who received a HER2-directed antibody either alone or in combination with chemotherapy. In some case reports, amniotic fluid index increased after use of a HER2-directed antibody was stopped. Animal Data There were no animal reproductive or developmental toxicity studies conducted with fam-trastuzumab deruxtecan-nxki.

Mechanism of action

12.1 Mechanism of Action Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to HER2 on tumor cells, fam-trastuzumab deruxtecan-nxki undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Exposure-Response Relationships Exposure-response relationship for efficacy has not been fully characterized. Higher systemic exposure to fam-trastuzumab deruxtecan-nxki was associated with a higher incidence rate of any grade ILD. Cardiac Electrophysiology At the dosage of ENHERTU 6.4 mg/kg every 3 weeks, a mean increase in the QTc interval >20 ms was not observed.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The median elimination half-life of fam-trastuzumab deruxtecan-nxki is 5.4 to 5.7 days.

The median elimination half-life of DXd is 5.4-6.1 days.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The pharmacokinetics of fam-trastuzumab deruxtecan-nxki and its payload DXd were evaluated in patients with cancer and are presented as mean (% coefficient of variation), unless otherwise specified. At a dose of 5.4 mg/kg, the maximum concentration (C max ss) of fam-trastuzumab deruxtecan-nxki is 132 µg/mL (20%) and of DXd is 4.7 ng/mL (48%) and the AUC ss of fam-trastuzumab deruxtecan-nxki is 772 µg∙day/mL (27%) and of DXd is 29 ng∙day/mL (48%).

At a dose of 6.4 mg/kg, the C max,ss of fam-trastuzumab deruxtecan-nxki is 126 µg/mL (18%) and of DXd is 5.2 ng/mL (42%) and the AUC ss of fam-trastuzumab deruxtecan-nxki is 743 µg∙day/mL (26%) and of DXd is 33 ng∙day/mL (43%), respectively. Following a single dose, C max and AUC of fam-trastuzumab deruxtecan-nxki and DXd increase in a dose proportional manner over a dose range of 3.2 mg/kg to 8 mg/kg (approximately 0.5 to 1.25 times the highest approved dose).

Accumulation of fam-trastuzumab deruxtecan-nxki is approximately 1.4-fold at steady-state (Cycle 3). Distribution The estimated volume of distribution of the central compartment (Vc) of fam-trastuzumab deruxtecan-nxki is 2.7 L (% CV 16%). DXd plasma protein binding is approximately 97% and the blood-to-plasma ratio is approximately 0.6 in vitro.

Elimination The median elimination half-life of fam-trastuzumab deruxtecan-nxki is 5.4 to 5.7 days. The estimated systemic clearance of fam-trastuzumab deruxtecan-nxki is 0.4 L/day (24%). The median elimination half-life of DXd is 5.4-6.1 days. The estimated systemic clearance of DXd is 18 L/h (28%). Metabolism The monoclonal antibody is expected to be degraded into small peptides and amino acids via catabolic pathways.

DXd is primarily metabolized by CYP3A4. Specific Populations No clinically significant differences in the pharmacokinetics of fam-trastuzumab deruxtecan-nxki or DXd were observed for age (20-96 years); race (Asian [48%] vs Non-Asian [52%]), including White (43%), and Black or African American (1.9%); sex; body weight (27-138 kg); tumor types; mild hepatic impairment; and mild or moderate renal impairment.

The pharmacokinetics of fam-trastuzumab deruxtecan-nxki or DXd in patients with moderate to severe hepatic impairment or severe renal impairment is unknown. Drug Interaction Studies Clinical Studies No clinically significant differences in pharmacokinetics of fam-trastuzumab deruxtecan-nxki or DXd were observed when used concomitantly with itraconazole (strong CYP3A inhibitor) or ritonavir (strong CYP3A inhibitor and OATP inhibitor).

In Vitro Studies CYP450 Enzymes: DXd does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A nor induce CYP1A2, CYP2B6, or CYP3A. UGT Enzymes: DXd is not a substrate of UGT. Transporter Systems: DXd is not an inhibitor of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, P-gp, BCRP, or BSEP. DXd is a substrate of OATP1B1, OATP1B3, MATE2-K, P-gp, MRP1, and BCRP.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Enhertu · Daiichi Sankyo Inc. [US FDA-approved label, version 28, May 15, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .